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General Background  
Renin is a proteolytic enzyme, produced in and secreted from the juxtaglomerular cells of 
the afferent arteriole.18  Renin is the rate-limiting enzyme of the renin-angiotensin system.  Renin 
cleaves the leucine-valine bond in circulating angiotensinogen, converting it to angiotensin I.26  
Angiotensin I is later converted by angiotensin converting enzyme to Angiotensin II, and 
Angiotensin II is the major effector molecule of the renin-angiotensin system.  The production of 
renin (and subsequently angiotensin II) is important for the regulation blood pressure, circulating 
volume and renal homeostasis.  This is illustrated by the fact that renin knockout mice have 
impaired viability, and those that do survive are profoundly hypotensive, are unable to 
concentrate urine, and have impaired renal development.79  Renin is also important in the 
pathogenesis of hypertension.  Approximately 70% of patients with hypertension have 
inappropriately elevated plasma renin levels.13  Inhibitors of the renin-angiotensin system 
(including direct inhibitors of renin) significantly decrease blood pressure and are a mainstay of 
anti-hypertensive therapy.  Thus, factors that affect renin secretion and regulation are of both 
scientific and clinical interest.  Renin can be quantified by several methods in vivo.  The most 
common method to quantitate renin is known as plasma renin activity (PRA).14  PRA is defined 
as the amount of Angiotensin I generated by plasma renin from angiotensinogen endogenous to 
the plasma.  PRA represents renin secreted from the JG cells, as bilaterally-nephrectomized 
patients or rats have their PRA levels fall to essentially undetectable levels.38,52 
PRA is decreased by elevated plasma calcium (Ca).40,41,74  This has been known for over 
30 years, but the mechanism by which it occurs is unknown.  Recently, it has been demonstrated 
that many of the effects of plasma Ca are mediated by a ubiquitously expressed calcium-sensing 
receptor (CaSR).12  The CaSR is a seven-transmembrane domain, G-protein-coupled receptor 
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that transmits changes in extracellular Ca into changes in intracellular signaling.  The CaSR is 
most highly expressed in tissues that are important for Ca metabolism, such as the parathyroid 
gland and kidney.  The concerted action of the CaSR in these various tissues is to 
homeostatically lower plasma Ca in response to hypercalcemia; the parathyroid-expressed CaSR 
decreases parathyroid hormone (PTH) secretion in response to elevated plasma Ca, and the CaSR 
expressed in the kidney promotes the excretion of Ca in response to hypercalcemia.  Since the 
CaSR inhibits PTH secretion from the chief cells of the parathyroid gland, it was hypothesized 
that the CaSR would mediate the inhibition of renin release by elevated extracellular Ca.  In 
support of this notion, the CaSR is expressed by juxtaglomerular (JG) cells in vitro in the renin-
containing granules, and CaSR agonists inhibit renin release in vitro.53,54  However, whether the 
CaSR mediates the high-Ca inhibition of PRA remains to be determined.  The intracellular 
mechanisms for how the CaSR inhibits renin release in vitro are well defined.  Cyclic adenosine 
monophosphate (cAMP) is the major stimulatory second messenger for renin release.  The CaSR 
inhibits the production of intracellular cAMP by decreasing the activity of a calcium-inhibitable 
isoform of adenylate cyclase (adenylate cyclase-V),55,56 and also by stimulating the activity of a 
Ca-activated, cAMP-degrading phosphodiesterase, PDE-1.53  Thus, the net effect of the CaSR is 
to decrease JG cell cAMP and inhibit renin release. 
We anticipate that elevated renal cortical interstitial Ca during hypercalcemia will be 
what inhibits PRA. In vivo, the renin secreting JG cells are bordered luminally by fenestrated 
endothelium.  It is possible that Ca could pass through these fenestrae to inhibit renin release 
directly from the JG cell, but seems unlikely as the endothelial cells are coupled to JG cells via 
the tight junction channels called connexins.73  Alternatively, the basolateral border of the JG 
cells is freely bathed in the renal cortical interstitium.  As such, changes in renal cortical 
interstitial Ca could affect PRA as well. Increasing plasma Ca increases renal cortical interstitial 
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Ca.48 We anticipate increased interstitial Ca will act on the CaSR to decrease PRA.  A brief 
review of renal Ca handling will highlight which transport processes we anticipate would most 
likely be responsible for the response of PRA to renal cortical interstitial Ca. 
Ca is found in predominantly two forms in the plasma: calcium that is bound to proteins 
(predominantly albumin) which is not filtered at the glomerulus, and filtered calcium.  Free, 
ionized calcium represents 80% of the filterable calcium, while the remainder is complexed to 
anions.80  Free, ionized Ca is the form of Ca which interacts with the CaSR.  Approximately 97-
99% of the filtered Ca load is reabsorbed by the kidney.  Of the filtered load of Ca, the proximal 
tubule is responsible for 50-70% of its reabsorption.80 Ca reabsorption in the proximal tubule 
closely follows water and NaCl reabsortion.80,1  The reabsorption of Ca occurs through the 
paracellular diffusion, presumably through claudin-2, a tight-junction protein.2,11,21  The thin 
descending limb does not reabsorb Ca.80  The thick ascending limb (THAL) of the Loop of 
Henle reabsorbs about 15% of the filtered load of Ca.80  The reabsorption of Ca occurs down a 
concentration gradient and is enhanced by the lumen positive electrical potential.9, 80  The lumen 
positive potential of the THAL is generated by the reabsorption of Cl-, and also by K secreted 
into the lumen through the ROMK channel.30  This increases the positivity of the lumen, which 
increases the driving force for passive, paracellular Ca reabsorption.9  Ca reabsorption occurs 
though the paracellular channel, claudin-16.64  The distal and connecting tubules are responsible 
for 10-15% of Ca reabsorption.80 In these nephron segments, Ca is reabsorbed transcellularly 
through TRPV5.33  PTH exerts its main hypocalciuric effects in these segments by stimulating 
the production and activity of TRPV5.17,19,32,33,69  Calbindin-D28K, a Ca-binding protein, is 
necessary for maintaining the high luminal to intracellular Ca gradient, allowing for Ca to flow 
down its concentration gradient into the distal tubule epithelia.32  Additionally, Vitamin D 
increases TRPV5 expression.32  While the amount of Ca reabsorbed in this segment is relatively 
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small, the distal tubule has a large effect on how much Ca is excreted, since much of the Ca 
reabsorption is under hormonal control.  The collecting duct is responsible for about 1% of Ca 
reabsorption, which occurs through TRPV6.80   
The CaSR also plays an important role in renal Ca handling.12  The CaSR is expressed 
almost ubiquitously throughout the nephron:  It has been detected in the proximal tubule, thick 
ascending limb, distal tubule and the cortical and medullary collecting ducts.60  It is found 
apically in both the proximal tubule and the inner medullary collecting duct.60  The CaSR is 
found basolaterally in the thick ascending limb, distal tubule and cortical collecting duct.60 In the 
proximal tubule, high tubular Ca inhibits the Na-K-ATPase transporter, ostensibly by acting on 
the CaSR.28  This may contribute to the diuretic effects of hypercalcemia.  In the THAL, 
activation of the basolateral CaSR decreases the secretion of K into the tubular lumen, which 
decreases the positive luminal voltage potential.12  This decreases the driving force for 
paracellular Ca reabsorption and increases Ca excretion.12  Also, in the THAL, activation of the 
CaSR inhibits cAMP production, and may inhibit Na-K-2Cl (NKCC-2) transporter trafficking, 
contributing to its diuretic effects.20  How the CaSR affects transport in the distal tubule and 
collecting duct is not well defined.   
PTH is an 84 amino acid peptide secreted from the chief cells of the parathyroid gland.  
PTH is released into the plasma in response to hypocalcemia.  PTH increases plasma Ca 
predominantly by increasing Ca resorption from bone and also by increasing the renal 
reabsorption of Ca.  There are 4 sites along the nephron where PTH may affect Ca reabsorption:  
the glomerulus, the proximal tubule, thick ascending limb, and distal tubule.  PTH acts to 
increase plasma Ca by inhibiting the filtering of Ca at the glomerulus by decreasing the filtration 
coefficient (Kf).36  In contrast, PTH paradoxically inhibits proximal tubule Ca reabsorption by 
inhibiting the Na-H exchanger (NHE) in the proximal tubule.16  Because Ca reabsorption is 
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coupled to the reabsorption of Na in the proximal tubule,1,80 this inhibition of NHE decreases Ca 
reabsorption in this nephron segment.1  However, distal Ca reabsorption compensates for this.  
PTH stimulates Ca reabsorption in the cortical THAL.22,43  PTH-stimulated Ca transport in the 
thick ascending limb occurs through a passive mechanism via paracellular pathways.10,37,77  It is 
not known if the PTH-mediated paracellular reabsorption pathway for Ca in the thick ascending 
limb occurs through claudin-16.  The best characterized effects of PTH on Ca reabsorption are in 
the distal tubule.17  Here, PTH stimulates the active transport of Ca via multiple mechanisms.  
First, PTH stimulates the synthesis and activity of the distal tubule Ca transporter, TRPV5.19,32,69  
The low intracellular to extracellular Ca gradient is maintained by the Ca-binding protein, 
Calbindin-D28K, in the distal tubule epithelia.  Ca is pumped into the renal interstitium by the 
Na-Ca antiporter or Ca-ATPases.  PTH stimulates the expression of the Na-Ca antiporter, which 
is responsible for approximately 75% of the basolateral Ca transport.33  The net effect of PTH on 
all of these reabsorptive processes in different nephron segments is to stimulate Ca reabsorption 
and inhibit urinary Ca excretion.33  This is reflected in the effects of PTH on renal cortical 
interstitial Ca:  PTH increases renal cortical interstitial Ca.48  As such, PTH is integral for 
increasing renal cortical interstitial Ca mainly due to it stimulatory effects on Ca reabsorption in 
the distal nephron. 
As such, we anticipate the following: since the CaSR has been shown to inhibit renin 
release in vitro, we anticipate that it should inhibit PRA in vivo as well.  Furthermore, we 
anticipate that hypercalcemia will also inhibit PRA by acting on the CaSR.  We anticipate that 
hypercalcemia will decrease PRA via increased renal cortical interstitial Ca.  Because PTH 
increases renal cortical interstitial Ca, we expect that hypercalcemia will increase renal cortical 
interstitial Ca in a PTH-dependent manner.  Thus, the overall hypothesis that we propose is; that 
hypercalcemia inhibits PRA via PTH-mediated increases in renal cortical interstitial Ca that act 
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on the CaSR triggering Ca-mediated inhibition of renin secretion. 
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CHAPTER 1: ACUTE ACTIVATION OF THE CALCIUM-SENSING RECEPTOR 
INHIBITS PLASMA RENIN ACTIVITY IN VIVO 
ABSTRACT 
In vitro, the renin-secreting juxtaglomerular cells express the calcium-sensing receptor, 
and its activation with the allosteric CaSR agonist, Cinacalcet, inhibits renin release.  To test if 
the activation of calcium-sensing receptor similarly inhibits plasma renin activity in vivo, we 
hypothesized that the calcium sensing receptor is expressed in juxtaglomerular cells in vivo, and 
acutely-administered Cinacalcet would inhibit renin activity in anesthetized rats.  Since 
Cinacalcet inhibits parathyroid hormone, which may stimulate renin activity, we sought to 
determine if Cinacalcet inhibits renin activity by decreasing parathyroid hormone.  Lastly, we 
hypothesized chronically administered Cinacalcet would inhibit basal and stimulated renin in 
conscious rats.  Calcium sensing receptors and renin were localized in the same juxtaglomerular 
cells using immunofluorescence in rat cortical slices fixed in vivo.  Cinacalcet was administered 
acutely via intravenous bolus in anesthetized rats and chronically in conscious rats by oral 
gavage.  Acute administration of Cinacalcet decreased basal renin activity from 13.6 ± 2.4 to 6.1 
± 1.1 ngAngI/ml/hr (p<0.001).  Likewise, Cinacalcet decreased furosemide-stimulated renin 
from 30.6 ± 2.3 to 21.3 ± 2.3 ngAngI/ml/hr (p<0.001).  In parathyroidectomized rats Cinacalcet 
decreased renin activity from 9.3 ± 1.3 to 5.2 ± 0.5 ngAngI/ml/hr (p<0.05) similar to sham-
operated controls (13.5 ± 2.2 to 6.6 ± 0.8 ngAngI/ml/hr, p<0.05).  Chronic administration of 
Cinacalcet over 7 days had no significant effect on plasma renin activity under basal or 
stimulated conditions.  In conclusion, calcium sensing receptors are expressed in juxtaglomerular 
cells in vivo, and acute activation of these receptors with Cinacalcet inhibits plasma renin activity 





The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that senses changes 
in extracellular calcium (Ca) and transmits these into parallel alterations in Ca-mediated 
intracellular signaling.31  The CaSR is expressed in the parathyroid and thyroid glands, intestines, 
and kidney.12,60  Stimulation of the CaSR inhibits parathyroid hormone (PTH) secretion, 
decreases plasma Ca and increases urinary Ca excretion.12  Calcimimetics, such as Cinacalcet-
HCl (Sensipar, Amgen Inc., Thousand Oaks, CA), increase the sensitivity of the CaSR to the 
ambient concentration of extracellular Ca.31  This leads to enhanced CaSR-mediated intracellular 
signaling at a given concentration of extracellular Ca.  Calcimimetics decrease plasma PTH and 
plasma Ca. Calcimimetics are used clinically to treat both secondary hyperparathyroidism and 
parathyroid carcinomas.31   
Renin is secreted from the juxtaglomerular (JG) cells in the afferent arteriole of the 
kidney and cleaves angiotensinogen to angiotensin I.7  Angiotensin I is the biological precursor 
for the vasoconstrictor agent, angiotensin II. The renin-angiotensin system is critical for blood 
pressure and volume homeostasis, and its inhibition is one mainstay of anti-hypertensive therapy.  
Furosemide stimulates renin secretion predominantly by stimulating nitric oxide and 
prostaglandin production from the macula densa.4,46  
Recently, we have shown that the CaSR is expressed in primary cultures of isolated, 
renin-secreting mouse JG cells, and CaSR activation with the allosteric CaSR agonist, 
Cinacalcet, inhibits renin release in vitro.54  Cinacalcet acts by decreasing the EC50 of the CaSR 
for extracellular Ca and has a terminal half-life in vivo of 30-40 hrs.15  It has been reported that 
Cinacalcet may acutely inhibit PRA in vivo,45 but whether Cinacalcet can inhibit PRA 
chronically is unknown.  Also, since Cinacalcet inhibits PTH, and PTH has been reported to 
stimulate PRA,66 we wanted to test if the inhibition of PRA by Cinacalcet was due to its ability 
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to decrease PTH.  Thus, we hypothesized that the CaSR is expressed in JG cells in vivo, that 
acutely-administered Cinacalcet would inhibit PRA in anesthetized rats, but that this stimulus 
would be eliminated by parathyroidectomy.  Finally, we hypothesized that chronically 
administered Cinacalcet would also inhibit PRA in conscious rats under basal and stimulated 
conditions. 
MATERIALS & METHODS 
Fixing the renal cortex in vivo: Male Sprague-Dawley rats were anesthetized using 125 
mg/kg body weight thiobutabarbitol, (Inactin, Sigma) I.P. before having their abdominal cavities 
opened and their left kidneys flushed with 150 mmol/L NaCl by retrograde perfusion through the 
abdominal aorta.  The kidney was then fixed in situ for 15 min via perfusion with 4% 
paraformaldehyde in buffer containing 150 mmol/L NaCl and 10 mmol/L sodium phosphate (pH 
7.4).  The kidney was removed and stored in 4% paraformaldehyde at 4° C until ready for 
slicing.  The poles of the kidney were sliced off, and the fixed renal cortex was embedded in 
paraffin. 5 μm slices were mounted on microscope slides for immunofluorescence experiments. 
Coimmunolabeling of renin and CaSR: Fixed, paraffin-embedded cortical slices were 
first de-paraffinized three times in Xylene, then hydrated gradually through graded alcohols: 
100% ethanol (2 times), 95% ethanol, 70% ethanol and finally distilled water.  All washes were 
for 5 min.  Slices were permeabilized with 0.1% Triton-X100 for 10 min at 37o C.  The CaSR 
was detected by incubating 1 hr at 37o C with a 1:40 dilution of the CaSR antibody (Affinity 
Bioreagents, Golden, CO) followed by incubating for 1 hr at 37o C with a 1:100 dilution of the 
secondary antibody (Alexa Fluor 488 goat antimouse IgG, Molecular Probes, Invitrogen Corp., 
Carlsbad, CA). Slides were then incubated for 1 hour at 37o C with a 1:25 dilution of an antibody 
raised in sheep against both rat and mouse renin (Innovative Research Inc., Novi, MI) followed 
by incubating for 1 hr at 37º C with a 1:100 dilution of secondary antibody (Alexa Fluor 568 goat 
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antisheep IgG, Molecular Probes). CaSR fluorescence was detected at 40X with a confocal laser 
scanning system (Visitech Intl., Confocal System, Sunderland, UK) set at 488 nm excitation with 
a 500 nm long-pass filter.  The same settings were used to detect renin, except that 568 nm 
excitation and a 590 nm band pass filter were used. 
Acute in vivo protocol:  
Male Sprague-Dawley rats (Charles River Laboratory, Wilmington, MA) weighing 250-
350 g were fasted overnight but allowed free access to water.  They were anesthetized using 
thiobutabarbital, 125 mg/kg body weight I.P. (Inactin, Sigma, St. Louis, MO) and placed on a 
heating pad to maintain constant body temperature. A tracheotomy was performed with PE-240 
tubing to allow spontaneous breathing of room air.  The femoral vein was catheterized with PE-
50 tubing for infusion of 10 μl/min 0.9% NaCl.  The femoral artery was catheterized with PE-50 
tubing attached to a Statham pressure transducer (Viggo-Spectramed, Oxnard, CA), calibrated 
using a “Traceable” electronic manometer (Fisher Scientific, Pittsburgh, PA), and connected 
through an iWorx 118 A to D Signal Processor to a computer using iWorx Labscribe 2.065 data 
acquisition software (iWorx, Dover, NH) for continuous monitoring of mean arterial pressure 
(MAP). 
After surgery, the rats received a supplemental bolus of 1.0 ml of 6% heat-inactivated 
bovine serum albumin (BSA, Sigma, St. Louis, MO) in normal saline and were allowed to 
equilibrate for 60 min.  All blood samples taken were 300 μL in volume, and were replaced with 
an equal volume of 6% BSA.  When the experiments were completed, the rats were euthanized 
by bilateral pneumothorax and aortic transection, and the kidneys decapsulated, excised and 
inspected for anatomical abnormalities. 
These procedures were reviewed and approved by our Institutional Animal Care and Use 
Committee (IACUC) and adhere to the guiding principles in the care and use of experimental 
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animals and conducted in accordance with the national Institutes of Health (NIH) Guide for the 
Care and Use of laboratory Animals. Henry Ford Hospital’s animal facility is AAALAC-
approved. 
Parathyroidectomy Procedure:   
Rats were anesthetized using 50 mg/kg bodyweight Nembutal (Pentobarbital Sodium, 
Ovation Pharmaceuticals, Deerfield, IL), I.P.  The surgical procedure was performed using 
aseptic techniques on a heating pad to maintain constant body temperature.  The anterior portion 
of the rat neck was shaved and swabbed with betadine (Purdue Frederick, Norwalk, CT).  A 
longitudinal incision on the anterior portion of the rat’s neck was made, and the connective tissue 
and underlying muscle was teased apart with forceps.  The parathyroid glands were isolated on 
the lateral, superior portion of the thyroid glands and were excised.  The incision was then 
sutured and stapled closed and covered with colloidion iodine.  Rats received 10 ml of 
subcutaneous sterile 0.9% NaCl immediately post-surgery to prevent dehydration.  Sham 
surgeries were performed identically, except the parathyroid glands were left intact.  Rats were 
used 24-48 hours post-surgery for acute protocols.  Parathyroidectomized rats were excluded 
from analyses if their basal plasma PTH was at all detectable by assay.   
In vivo protocols: 
I. The effect of acutely-administered Cinacalcet on basal PRA:   
Group 1: Cinacalcet 5 mg/kg:  When the rats finished recovering after the surgical 
procedure, blood was withdrawn for a basal PRA.  The rats then received a 5 mg/kg I.V. bolus of 
Cinacalcet, dissolved in dimethylsulfoxide (DMSO) and diluted into 500 µl of 0.9% NaCl.  
Samples of blood were withdrawn for PRA at 15, 30 and 60 minutes post-Cinacalcet.  Blood for 
measurement of parathyroid hormone (PTH) and plasma Ca was withdrawn at 60 minutes post-
Cinacalcet after the final PRA sampling (n=7).  Cinacalcet was purchased from the Henry Ford 
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Hospital Pharmacy, and was not provided by Amgen or any intermediary supplier. 
Group 2: Cinacalcet 1 mg/kg:  Protocols were run identically to group 1, except that the 
rats received only 1 mg/kg Cinacalcet I.V. (n=8). 
Group 3: vehicle: Protocols were run identically to group 1, except that the rats received 
an equal volume of the DMSO vehicle without Cinacalcet (n=11). 
II. The effects of acutely-administered Cinacalcet on plasma Ca and PTH over time: 
Additional protocols were run identically to Protocol I, except that plasma PTH and Ca 
were measured basally, and at each of the15, 30 and 60 minutes time points post-Cinacalcet or 
vehicle bolus. 
III. The effect of acutely-administered Cinacalcet on furosemide-stimulated PRA:   
Group 1: Cinacalcet 5 mg/kg + furosemide: Rats were anesthetized and instrumented as 
described.  After recovery from surgical instrumentation, while still under anesthesia, rats 
received an I.V. bolus of 5 mg/kg furosemide1 (American Regent, Inc., Shirley, NY) and 30 
minutes later blood was withdrawn to determine furosemide-stimulated PRA.  Next, rats 
received a 5 mg/kg I.V. bolus of Cinacalcet.  Blood was withdrawn for PRA measurements at 15, 
30 and 60 minutes post-Cinacalcet.  Blood for the measurement of PTH and plasma Ca was 
withdrawn at 60 minutes post-Cinacalcet after the final PRA sampling (n=8). 
Group 2: vehicle + furosemide: Protocols were run identically to group 1, except that the 
rats received an equal volume of the DMSO vehicle without Cinacalcet (n=9). 
IV. The effect of acutely-administered Cinacalcet in parathyroidectomized (PTX) rats:   
Group 1: Cinacalcet 5 mg/kg + PTX:  PTX rats received a 5 mg/kg I.V. bolus of 
Cinacalcet after having basal PRA, PTH and plasma Ca samples taken. PRA samples were taken 
at 15, 30 and 60 minutes post-Cinacalcet.  Blood for measurement of parathyroid hormone 
(PTH) and plasma Ca was withdrawn prior to Cinacalcet administration and at 60 minutes post-
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Cinacalcet after the final PRA sampling (n=4).   
Group 2: Cinacalcet 5 mg/kg + sham:  Experiments were run identically to group 1, 
using sham-operated rats (n=7). 
V. Chronic protocols with Cinacalcet via oral gavage:  
Chronic studies included both basal and stimulated PRA in unanesthetized, conscious 
rats.  Rats with unstimulated PRA received 10 mg/kg bodyweight Cinacalcet via oral gavage. 
Cinacalcet was administered once per day in 500 μl of 3.3% glucose.  Vehicle control rats 
received identical treatment with 3.3% glucose, but did not receive Cinacalcet.  After 7 days of 
receiving Cinacalcet or the vehicle, blood was collected by decapitation for PRA and plasma Ca 
measurements.  Cinacalcet has a half-life of 30-40 hours post-absorption.15  Seven days was 
chosen because steady-state levels of the drug are achieved within this time frame.15  Only the 
first 3 seconds of blood after decapitation were collected for PRA to ensure renin released by the 
baroreceptor mechanism did not contaminate the sample.  Both the Cinacalcet and vehicle 
groups had an n=6. 
In the study examining the chronic effect of Cinacalcet on stimulated PRA, 25 mg/kg 
Losartan Potassium (Sigma, St. Louis, MO) was delivered in 0.9% NaCl via oral gavage, while 
20 mg/kg Furosemide (Hospira, Lake Forest, IL) was delivered via an I.P. injection.4,6  
Cinacalcet (20 mg/kg bodyweight) was delivered daily via oral gavage identically as above.  
Vehicle control rats received identical treatment, but did not receive Cinacalcet.  All drugs were 
given once per day for 7 days before blood was collected via decapitation identically to rats with 
unstimulated PRA.  Blood for plasma Ca and PTH measurements was also collected.  The 
Cinacalcet group had an n=9, and the vehicle control group had an n=11. 
Plasma Renin Activity (PRA): PRA was analyzed from 300 μl of femoral venous blood.  
Blood was centrifuged at 9800 x g for 6 min and the plasma was aspirated and stored at -20° C 
14 
 
until PRA was determined.  Plasma renin activity was analyzed by generation of angiotensin I 
(Ang I/ hr/min) using a Gamma Coat RIA kit (DiaSorin, Stillwater, MN) as previously described 
and according to the manufacturers instructions.  The minimum resolution we can obtain with 
our assay is 0.13 ng Ang I/ml/hr. 
Plasma Ca and PTH measurements: Measurements of plasma Ca and PTH were 
performed on femoral venous blood samples.  Plasma Ca was measured using a NOVA-1 
electrolyte analyzer (Nova Biomedical, Waltham, MA) while plasma PTH was measured using a 
commercial, rat PTH immunoassay kit (Alpco Diagnostics, Salem, NH) according to the 
manufacturer’s instructions. 
Statistics: Changes from baseline to post-treatment were analyzed using One-way 
Repeated-measures ANOVA with a Student-Newman-Keuls test for post-hoc analysis for 
multiple measurements, while single measurements post-baseline were measured using a paired 
t-test.  Intergroup comparisons comparing multiple groups were performed using a One-way 
ANOVA with a Student-Newman-Keuls test for post-hoc analyses; while single intergroup 
comparisons were performed using a Student’s unpaired t-test.  For intergroup comparisons of 
PRA, the values were transformed to a percentage of their basal value.  The appropriate 
intergroup test was used on these transformed values at their specific time points.  Values p < 
0.05 were considered statistically significant in all cases.  All data are presented as mean ± SEM. 
RESULTS 
Coimmunolabeling of renin and CaSR: Figure 1 represents two cortical sections (A 
and B) labeled for the CaSR and renin.  The left panels illustrate the expression of the CaSR 
(green), which is found throughout the proximal tubule as expected,60 as well as the afferent 
arteriole (aa) next to the glomerulus (G), while the glomeruli were completely negative.  The 
right panels show the expression of renin (red) within the same JG cells found in the afferent 
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arteriole.  The immunolabeling demonstrates that the CaSR is localized in the renin-containing 
JG cells in the afferent arteriole in rat renal cortical slices fixed in vivo. 
 
Figure 1: Fluorescent microscopy at 40X showing renin (red) is expressed with the CaSR 
(green) in the afferent arteriole in two different rat renal cortical slice images (A and B) fixed in 
vivo.  aa: afferent arteriole, G: glomerulus. 
 
I. The effect of acutely-administered Cinacalcet on basal PRA:   
To test whether acute activation of the CaSR inhibited basal PRA in vivo, we treated 
anesthetized rats with the vehicle control, 1 mg/kg Cinacalcet or 5 mg/kg Cinacalcet.  The basal 
PRA for the vehicle control group was 12.7 ± 2.7 ng Ang I/ml/hr and was unchanged at 15, 30 
and 60 minutes post-vehicle (11.1 ± 2.6, 11.0 ± 2.7 and 10.5 ± 1.9 ng Ang I/ml/hr, respectively).  
The basal PRA in the 1 mg/kg Cinacalcet group was 16.2 ± 2.0 ng Ang I/ml/hr.  1mg/kg 
Cinacalcet significantly decreased PRA at 15, 30 and 60 minutes post-1 mg/kg Cinacalcet to 9.3 
± 1.4 (p<0.001), 8.8 ± 2.0 (p<0.001) and 10.4 ± 1.8 ng Ang I/ml/hr (p<0.001), respectively.  The 
basal PRA in the 5 mg/kg Cinacalcet group was 13.6 ± 2.4 ng Ang I/ml/hr.  5 mg/kg Cinacalcet 
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significantly decreased PRA at 15, 30 and 60 minutes post-5 mg/kg Cinacalcet to 6.9 ± 1.2 
(p<0.001), 6.1 ± 1.1 (p<0.001) and 8.2 ± 1.7 ng Ang I/ml/hr (p<0.001), respectively.   
 
Figure 2: The acute effects of 
Cinacalcet on basal PRA in 
anesthetized rats. 5 mg/kg and 1 
mg/kg Cinacalcet significantly 
decreased PRA at 15, 30 and 60 
minutes post-treatment, 
respectively. PRA in the vehicle-
treated group did not change. 
***p<0.001 versus basal. N=7-11. 
 
Basal MAP in the vehicle group 1 mg/kg and 5 mg/kg Cinacalcet-treated groups were 98 
± 2, 100 ± 3 and 107 ± 6 mm Hg, respectively.  MAP did not change during or after Cinacalcet 
administration at either dose.  We measured both plasma Ca and PTH at the end of the protocol 
as positive controls.  In the vehicle control group, plasma Ca was 1.24 ± 0.02  mmol/L, while in 
the 1 mg/kg Cinacalcet-treated group and 5 mg/kg Cinacalcet group it was 0.94 ± 0.02 mmol/L 
(p<0.001) and 0.97 ± 0.02 mmol/L (p<0.001), respectively.  Plasma PTH was 114.2 ± 15.1 pg/ml 
in the vehicle-treated group, 36.0 ± 12.6 in the 1 mg/kg Cinacalcet group (p<0.001) and 26.0 ± 
8.3 pg/ml in the 5 mg/kg Cinacalcet-treated group (p<0.001). 
II. The effects of acutely-administered Cinacalcet on plasma Ca and PTH over time:   
We measured the effects of Cinacalcet on plasma Ca and PTH to test whether Cinacalcet 
decreased plasma Ca and PTH at all time points in which PRA was measured.  Anesthetized rats 
received the vehicle control, 1 mg/kg Cinacalcet or 5 mg/kg Cinacalcet.  The basal plasma Ca in 
the 5 mg/kg Cinacalcet group was 1.27 ± 0.03 mmol/L.  The basal plasma Ca in the vehicle-
treated group was 1.20 ± 0.02 mmol/L and did not significantly change and 15, 30 or 60 minutes 
post-vehicle (1.23 ± 0.05 mmol/L, 1.25 ± 0.04 mmol/L, 1.27 ± 0.03 mmol/L).  The basal plasma 
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Ca in the 1 mg/kg Cinacalcet group was 1.30 ± 0.02 mmol/L.  1 mg/kg Cinacalcet significantly 
decreased plasma Ca at 15, 30 and 60 minutes post-1 mg/kg Cinacalcet to 1.10 ± 0.08 mmol/L 
(p<0.05), 1.10 ± 0.02 mmol/L (p<0.05) and 1.07 ± 0.04 mmol/L (p<0.01), respectively.  5 mg/kg 
Cinacalcet significantly decreased plasma Ca at 15, 30 and 60 minutes post-5 mg/kg Cinacalcet 
to 1.13 ± 0.01 mmol/L (p<0.01), 1.08 ± 0.02 mmol/L (p<0.01) and 0.98 ± 0.02 mmol/L 
(p<0.001), respectively. 
The basal PTH in the vehicle-treated group was 117.3 ± 23.1 pg/ml and did not 
significantly change and 15, 30 or 60 minutes post-vehicle (107.9 ± 17.2 pg/ml, 86.7 ± 7.9 
pg/ml, 123.1 ± 0.5 pg/ml).  The basal PTH in the 1 mg/kg Cinacalcet group was 162.5 ± 9.9 
pg/ml.  1 mg/kg Cinacalcet significantly decreased plasma Ca at 15, 30 minutes post bolus to 
undetectable levels (p<0.001), and 26.9 ± 14.3 pg/ml (p<0.001) at 60 minutes post-bolus.  The 
basal PTH in the 5 mg/kg Cinacalcet group was 118.9 ± 34.1 pg/ml.  5 mg/kg Cinacalcet 
significantly decreased PTH to undetectable levels (p<0.01) 15 minutes post-bolus, 11.4 ± 11.4 
pg/ml (p<0.01) 30 minutes post-bolus, and again to undetectable levels (p<0.05) 60 minutes 
post-bolus.     
III. The effect of acutely-administered Cinacalcet on furosemide-stimulated PRA:  
To test whether acute activation of the CaSR with Cinacalcet can inhibit stimulated PRA, 
we tested the effects of Cinacalcet after administering furosemide to anesthetized rats.  The 
furosemide-stimulated PRA in the vehicle control group was 36.9 ± 4.2 ng Ang I/ml/hr and 
remained elevated at 15, 30 or 60 minutes post-vehicle (34.4 ± 3.6, 32.5 ± 3.4 ng Ang I/ml/hr 
and 29.3 ± 3.7 ng Ang I/ml/hr, respectively).  Furosemide-stimulated PRA in the Cinacalcet 
group began at 30.6 ± 2.3 ng Ang I/ml/hr, but was significantly and consistently decreased 15, 30 
and 60 minutes post-Cinacalcet to 21.3 ± 2.3 (p<0.001), 22.5 ± 2.2 (p<0.001) and 21.9 ± 1.9 ng 
Ang I/ml/hr (p<0.001), respectively (Figure 3).   
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Figure 3: The acute effects of 
Cinacalcet on Furosemide-
stimulated PRA in anesthetized 
rats.  5 mg/kg Cinacalcet 
significantly decreased PRA at 15, 
30 and 60 minutes post-treatment, 
respectively. PRA in the vehicle-
treated groups did not change at 15, 
30 and 60 minutes post-treatment, 
respectively. *** p<0.001 versus 




MAP after furosemide was 115 ± 4 mm Hg.  Cinacalcet slightly, but significantly, 
increased MAP to 121 ± 4, 15 minutes post-administration (p<0.05).  MAP returned to normal at 
30 minutes (115 ± 4 mm Hg) and decreased at 60 minutes to 107 ± 3 (p<0.001). 
We also measured the effect of Cinacalcet on plasma Ca and PTH in the presence of 
furosemide.  Plasma Ca was lower in the presence of Cinacalcet plus furosemide (0.92 ± 0.05 
mmol/L) versus the vehicle and furosemide group (1.24 ± 0.03 mmol/L, p<0.001,), while plasma 
PTH was lower in the Cinacalcet plus furosemide group (27.1 ± 7.1 pg/ml) compared to the 
vehicle plus furosemide group (123.7 ± 20.4 pg/ml, p<0.001). 
IV. The effect of acutely-administered Cinacalcet in PTX rats:   
To determine if Cinacalcet inhibits PRA independently of its effects on plasma Ca and 
PTH, we used PTX rats.  Basal PRA in the sham-operated group was 13.5 ± 2.2 ng Ang I/ml/hr 
and, similar to the PTX group, decreased significantly 15 and 30 minutes post-Cinacalcet to 6.6 
± 0.8 ng Ang I/ml/hr (p<0.05) and 6.6 ± 1.5 ng Ang I/ml/hr (p<0.05), respectively.  PRA at 60 
minutes post-Cinacalcet was not significantly different (11.3 ± 2.6 ng Ang I/ml/hr).  Basal PRA 
in the PTX group was 9.3 ± 1.3 ng Ang I/ml/hr and decreased 15 and 30 minutes post-Cinacalcet 
to 5.2 ± 0.5 ng Ang I/ml/hr (p<0.05) and 5.8 ± 0.9 ng Ang I/ml/hr (p<0.05), respectively.  PRA 
at 60 minutes post-Cinacalcet was not significantly different (8.6 ± 0.5 ng Ang I/ml/hr).     
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Figure 4: The acute effects of 
Cinacalcet on unstimulated PRA 
in anesthetized, para-
thyroidectomized (PTX) or sham 
rats. In the PTX group, 5 mg/kg 
Cinacalcet significantly decreased 
PRA at 15 and 30 minutes post-
Cinacalcet.  However, PRA was 
not significantly reduced at 60 
minutes in the PTX group.  In the 
sham-operated group, 5 mg/kg 
Cinacalcet significantly decreased 
PRA at 15 and 30 minutes post-
Cinacalcet but not at 60 minutes.  
No differences between PRA 
values were found between 
groups at any time point. *p<0.05 
vs. basal. N=4-7. 
 
Basal MAP was 108 ± 3 mm Hg in the PTX rats, and 113 ± 4 mm Hg in the sham-
operated rats.  Cinacalcet did not change the MAP in either group.  In the PTX group, basal 
plasma Ca was 0.85 ± 0.07 mmol/L and did not change in response to Cinacalcet (0.77 ± 0.02 
mmol/L).  Basal plasma Ca was 1.12 ± 0.08 mmol/L in the sham group, and decreased to 0.80 ± 
0.09 after Cinacalcet (p<0.001).  Basal PTH was undetectable in the PTX group before and after 
Cinacalcet.  Basal PTH in the sham group was 98.3 ± 23.2 pg/ml and decreased to 45.3 ± 17.5 
pg/ml after Cinacalcet (p<0.01). 
V. Chronic protocols with Cinacalcet via oral gavage:  
We tested whether chronic activation of the CaSR with Cinacalcet could inhibit PRA in 
conscious rats under unstimulated and stimulated conditions.  In the unstimulated groups, the 
PRA after 7 days of vehicle treatment was 1.6 ± 0.2 ng Ang I/ml/hr and 1.3 ± 0.2 ng Ang I/ml/hr 
with Cinacalcet treatment.  PRA in the groups were not significantly different.    
In a second set of rats, PRA was stimulated chronically by Furosemide plus Losartan 
with or without Cinacalcet over 7 days.  The PRA in the stimulated, vehicle-treated rats was 32.1 
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± 2.5 ng Ang I/ml/hr while the stimulated, Cinacalcet-treated rats was 38.1 ± 4.5 ng Ang I/ml/hr.  
Thus, the PRA values with Cinacalcet-treatment did not differ from the vehicle-treatment under 
either basal or stimulated conditions.    
Since Cinacalcet, if acting on CaSR, should decrease plasma Ca, we measured the plasma 
Ca in each group as a positive control.  The plasma Ca was lower (0.88 ± 0.03 mmol/L) in the 
Cinacalcet-treated group compared to 1.02 ± 0.03 mmol/L in the vehicle-treated group under 
unstimulated conditions (p<0.01).  Similarly, plasma Ca was lower in the Cinacalcet-treated rats 
under stimulated conditions compared to vehicle-controls (0.66 ± 0.04 vs. 1.02 ± 0.03, p<0.001).  
As an additional positive control, we measured PTH in the groups with stimulated PRA.  As 
expected, PTH was lower (57.6 ± 6.6 pg/mL) in the Cinacalcet-treated group compared to 97.0 ± 
9.8 pg/ml in the control group (p<0.01). 
DISCUSSION 
We have shown that the CaSR coexpresses with renin in the rat renal cortex in vivo.  We 
found that activation of the CaSR with Cinacalcet, similar to our in vitro results, inhibited basal 
and stimulated PRA when applied acutely, and that this result was maintained even after the 
removal of PTH by parathyroidectomy.  Thus, our data support our hypothesis that sensitization 
of the CaSR in vivo with Cinacalcet acutely suppresses plasma renin activity.  
Renin colocalizes with the CaSR in primary cultures of JG cells from mice.54  However, 
to ensure that the colocalization in vitro is not artifact, we demonstrated that renin and the CaSR 
immunofluorescence localize in the same cells in rat renal cortical slices fixed in vivo.  Our 
immunofluorescence results provide further evidence of the localization of the CaSR on the JG 
cells, consistent with previous reports in vitro53,54 and in vivo45.   
The ability of Cinacalcet to inhibit PRA is consistent with our previous in vitro data 
demonstrating that the CaSR inhibits renin release from isolated JG cells.  The activation of the 
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CaSR inhibits adenylyl cyclase and decreases cellular cyclic AMP (cAMP) production.55-56  
cAMP is the key second messenger for stimulating renin secretion, and stimuli that decrease 
cAMP similarly decrease renin.7  Our studies in isolated JG cells have shown that the acute 
application of Cinacalcet inhibits both renin release and JG cell cAMP accumulation.54  The 
NKCC transport inhibitor, Furosemide, also stimulates renin secretion by increasing JG cell 
cAMP via macula densa-derived PGE2 production.50  Our data demonstrate that Cinacalcet 
inhibits Furosemide-stimulated PRA, which is consistent with our findings that acute activation 
of the CaSR inhibits renin secretion by directly inhibiting adenylyl cyclase isoform V and JG cell 
cAMP production27,53-56, thus blunting the adenylyl cyclase response to classical stimuli for renin 
secretion. 
To show that the Cinacalcet was given at an effective dose, we also measured the 
responses of plasma Ca and PTH.  Calcimimetics are used to treat primary and secondary 
hyperparathyroidism, as they lower plasma Ca and PTH by increasing the sensitivity of the 
CaSR to the ambient concentration of extracellular Ca.31  As expected, at 60 minutes post-
Cinacalcet the plasma Ca and PTH were significantly decreased in the Cinacalcet-treated groups 
compared to vehicle controls in both the presence and absence of furosemide.  Similar reductions 
in plasma Ca and PTH were seen in chronically treated conscious rats.  These observations 
indicate that Cinacalcet increased the sensitivity of the CaSR to extracellular Ca under all of our 
experimental conditions.  
We also tested the effect of Cinacalcet on plasma Ca and PTH at all intermediate time 
points, to determine whether there was a temporal relationship between the changes in basal 
PRA, Ca and PTH.  Cinacalcet decreased PRA versus basal levels at 15, 30 and 60 minutes post-
Cinacalcet.  Plasma Ca values decreased progressively at all 3 time points in response to either 
the 5 mg/kg or 1 mg/kg Cinacalcet bolus.  Different still was the response of PTH to Cinacalcet.  
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PTH was maximally inhibited at 15 minutes, and this inhibition was maintained across all time 
points.  
We also studied the effects of Cinacalcet on PRA in parathyroidectomized rats.  The 
acute infusion of PTH has been reported to increase PRA in dogs, 66 and parathyroidectomies can 
decrease PRA in patients with hyperparathyroidism and may help normalize blood 
pressure.13,25,27   To test if Cinacalcet decreased PRA by inhibiting PTH, we repeated our acute 5 
mg/kg Cinacalcet experiments in PTX rats.  PTH levels were undetectable in the PTX rats, while 
Cinacalcet decreased PTH levels in the sham controls.  Furthermore, the PTX rats were 
hypocalcemic compared to the sham controls, indicating the PTX procedure was successful.  
Cinacalcet decreased PRA just as efficaciously in the PTX rats compared to the shams.  Thus, 
our data suggest Cinacalcet decreases PRA independently of its inhibitory effects on PTH. 
High concentrations of Cinacalcet have been reported to acutely increase blood 
pressure.23  Thus, we measured MAP in our experiments to ensure that any decreases in PRA we 
detected were not due to pressor effects working through the renal baroreceptor mechanism.  
While Cinacalcet did not significantly increase MAP in most of our acute protocols, MAP was 
slightly and transiently elevated at 15 minutes post- 5 mg/kg Cinacalcet, though only in the 
furosemide-treated group.  Since 5 mg/kg Cinacalcet affected MAP in this protocol, we tested 
the effect of 1 mg/kg Cinacalcet on PRA.  1 mg/kg Cinacalcet had no effect on MAP at any time 
point, but also inhibited PRA to the same extent as the 5 mg/kg Cinacalcet dose.  There were no 
other effects on MAP by Cinacalcet in any other protocol.  Thus, the effects of Cinacalcet on 
PRA appear to be independent of its effects on blood pressure. 
While Cinacalcet decreased PRA, this was not accompanied by a hypotensive response 
due to the decrease in PRA.  This is not surprising, as renin secretion can undergo acute changes 
that have no effect on blood pressure or other cardiovascular parameters within the time frame of 
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our protocols.5   
While we were able to demonstrate that Cinacalcet could acutely inhibit PRA, Cinacalcet 
failed to inhibit both basal and stimulated PRA when given chronically over 7 days by oral 
gavage.  Since we observed Ca and PTH decreased with this administration, indicates that 
Cinacalcet was applied successfully.  Cinacalcet increases the sensitivity of the CaSR for 
extracellular Ca by decreasing the EC50 for the CaSR for extracellular Ca.  One reason the 
chronic administration of Cinacalcet may not have decreased PRA was because plasma Ca 
decreased significantly.  Thus, even though the CaSR would be acting at a lower “set point” for 
extracellular Ca, a lower concentration of extracellular Ca acting on the CaSR should produce 
lower CaSR activity.  In support of this notion, we notice that when we keep extracellular Ca 
constant in primary cultures of JG cells, Cinacalcet significantly decreases renin release, even 
after exposure to JG cells for 2 hrs.55    Additionally, one critique of our work was that using 
Losartan may be a suboptimal choice from chronically elevating PRA, since the AT-1 receptor 
acts through Gi subunits to exert many of its G-protein coupled effects in various tissues.63  
Additionally, the CaSR may act through Gi in some tissues.12  However, this was unlikely to 
affect our results, as we have shown in vitro that inhibiting Gi with pertussis toxin has no effect 
on the CaSR-mediated inhibition of renin release (unpublished observation). 
Another possible reason Cinacalcet only inhibited PRA acutely was due to the presence 
of barbiturate (Inactin) anesthesia in the acute experiments, but not the chronic ones.  Barbiturate 
anesthesia, including Inactin, increases PRA.24,34,58  This would account for the elevated basal 
PRA in our anesthetized rats versus the basal PRA in our unanesthetized rats receiving chronic 
treatment.  While this elevation of PRA by barbiturates may occur via adrenergic stimulation58, 




The inverse relationship between extracellular Ca and renin secretion has been referred to 
as the “calcium paradox”.27,56  Previous work has shown that extracellular Ca inhibits renin 
release in vitro by stimulating the CaSR,54 which decreases the activity of a calcium-inhibitable 
isoform of adenylyl cyclase and increases the activity of a calcium-sensitive 
phosphodiesterase.53,55,56  Our data suggest that this pathway is not just an isolated in vitro 
phenomenon, and that this pathway described in vitro is consistent with the acute response we 
observe in vivo.  Importantly, these data support the concept that Ca regulates renin by 
modulating the enzymes controlling cellular cAMP levels (adenylyl cyclase and 
phosphodiesterase), and thus, renin secretion.53-56  However, our data suggest that chronic 
treatment with Cinacalcet is unlikely to have any long-term effects on PRA, indicating that 
Cinacalcet will not have any deleterious effects on the PRA levels in patients taking these drugs. 
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CHAPTER 2: HYPERCALCEMIA REDUCES PLASMA RENIN VIA PARATHYROID 
HORMONE, RENAL INTERSTITIAL CALCIUM, AND THE CALCIUM-SENSING 
RECEPTOR 
ABSTRACT 
Acute hypercalcemia inhibits plasma renin activity.  How this occurs is unknown.  We 
hypothesized that acute hypercalcemia inhibits plasma renin activity via the calcium-sensing 
receptor due to parathyroid hormone-mediated increases in renal cortical interstitial calcium via 
TRPV5.  To test our hypothesis, acute in vivo protocols were run in sodium-restricted, 
anesthetized rats.  TRPV5 mRNA was measured with real-time quantitative RT-PCR.  Acute 
hypercalcemia significantly decreased plasma renin activity by 37% from 32.0 ± 3.3 to 20.3 ± 
2.6 ng Ang I/ml/hr (p<0.001).  Acute hypercalcemia also significantly increased renal cortical 
interstitial calcium by 38% (1.73±0.06 mmol/L) compared to control values (1.25±0.05 mmol/L, 
p<0.001).  Plasma renin activity did not decrease in hypercalcemia in the presence of a calcium-
sensing receptor antagonist, Ronacaleret (22.8±4.3 vs. 21.6±3.6 ng Ang I/ml/hr).  Increasing 
plasma calcium did not decrease plasma renin activity in parathyroidectomized rats (22.5 ± 2.6 
vs. 22.0 ± 3.0 ng Ang I/ml/hr).  Parathyroidectomized rats were unable to increase their renal 
cortical interstitial calcium in response to hypercalcemia (1.01±0.11 mmol/L).  Acutely replacing 
plasma parathyroid hormone levels did not modify the hypercalcemic inhibition of plasma renin 
activity in parathyroid-intact rats (39.1±10.9 vs. 16.3±3.2 ng Ang I/ml/hr, p<0.05).  TRPV5 
mRNA was decreased by 67% in parathyroidectomized rats (p<0.001).  Our data suggest that 
acute hypercalcemia inhibits plasma renin activity via the calcium-sensing receptor due to 
parathyroid hormone-mediated increases in renal cortical interstitial calcium via TRPV5.  
INTRODUCTION 
Renin secretion has a unique relationship with extracellular calcium (Ca) in that increased 
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extracellular Ca inhibits renin release both in vitro and in vivo.  In vitro, increased extracellular 
Ca inhibits renin release from juxtaglomerular (JG) cells by inhibition of adenylyl cyclase V and 
stimulation of phosphodiesterase-1C, thus decreasing cAMP, the stimulatory second messenger 
for renin release.53-56  In vivo, acute hypercalcemia also decreases renin secretion.40,41,74  
However, how hypercalcemia Ca inhibits renin secretion is unknown.  
It is possible that hypercalcemia inhibits renin by acting on the calcium-sensing receptor 
(CaSR).  To test this, we will use a CaSR antagonist on hypercalcemia-inhibited PRA. The CaSR 
is ubiquitously expressed and senses changes in extracellular Ca, transducing these changes into 
intracellular signaling.12  In vivo, the CaSR is integral for maintaining homeostatic control of 
plasma Ca.  It does so primarily by decreasing parathyroid hormone (PTH) secretion and renal 
Ca reabsorption in response to hypercalcemia.12  Recently, we have found that the renin-
secreting JG cells express the CaSR, and that stimulating the CaSR decreases renin release in 
vitro53,54 and plasma renin activity (PRA) in vivo.3  However, due to the ubiquitous expression of 
the CaSR, it is unknown how increases in plasma Ca could be translated into CaSR-mediated 
inhibition of renin secretion.  The basolateral surface of the JG cells is bathed in the renal cortical 
interstitium.7  Thus, in addition to increased plasma Ca, increased renal cortical interstitial Ca 
could directly stimulate the CaSR to inhibit renin secretion.  Increasing plasma Ca has been 
shown to increase renal cortical interstitial Ca.48  However, whether increased renal cortical 
interstitial Ca inhibits renin secretion is unknown. 
PTH is an 84 amino-acid peptide released from the chief cells of the parathyroid gland.  
PTH increases plasma Ca, primarily by stimulating Ca resorption from bone and Ca reabsorption 
in the kidney.  PTH may stimulate Ca reabsorption in the cortical thick ascending limb through 
paracellular pathways.  It is unknown if this increase in Ca reabsorption occurs through the 
paracellular Ca reabsorption channel, claudin-16.  PTH stimulates the renal Ca reabsorption, 
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predominantly in the distal tubule via TRPV5, the distal tubule epithelial Ca transporter.33  PTH 
increases the expression of TRPV5 and also increases TRPV5 Ca transport.19,69  These actions of 
PTH translate into increases in renal cortical interstitial Ca.48  As such, hypercalcemia may 
inhibit renin secretion via PTH-mediated increases in renal cortical interstitial Ca through 
TRPV5.    
With these considerations, we hypothesized that acute hypercalcemia inhibits plasma 
renin activity (PRA) via the CaSR due to PTH-mediated increases in renal cortical interstitial Ca 
via TRPV5. 
MATERIALS & METHODS 
Acute in vivo preparation:  Male Sprague-Dawley rats were placed on a 0.05% NaCl 
(Harlan-Teklad, Madison, WI) diet for 10 days prior to in vivo experimentation.  The low NaCl 
diet was used to stimulate PRA.40  Stimulation of basal PRA using dietary sodium restriction was 
used to amplify the possible inhibition of PRA in response to hypercalcemia.  Furthermore, it has 
been reported that high Ca infusions inhibit elevated PRA more efficaciously than basal 
PRA.40,41  Rats were fasted overnight prior to being anesthetized with 125 mg/kg body weight 
thiobutabarbitol (Inactin, Sigma, St. Louis, MO) and placed on heating pad for the duration of 
the experiment.  Rats were then given a tracheotomy using PE-240 tubing (Clay/Adams Becton 
Dickinson, Parsipanny, NJ).  The femoral vein was catheterized using PE-50 tubing and a 
maintenance infusion of 10 l/min of 0.9% NaCl was given.  The femoral artery was 
catheterized with PE-50 tubing attached to a Statham pressure transducer (Viggo-Spectramed, 
Oxnard, CA), and connected through an iWorx 118 A to D Signal Processor to a computer using 
iWorx Labscribe 2.065 data acquisition software (iWorx, Dover, NH) for continuous monitoring 
of mean arterial pressure (MAP).  The pressure transducers were calibrated using a digital, 
mercury-free “traceable” manometer (Fisher Scientific, Pittsburgh, PA).  The peritoneal cavity 
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was opened with a midline incision, and the intestines were wrapped with wet gauze and gently 
moved under the right abdominal wall to expose the left kidney.  A dialysis catheter, consisting 
of a single 1-cm strand of dialysis tubing (Hemoflow F-8, Fresenius, Waltham, MA) fused to two 
sections of PE-20 tubing using nail polish (Revlon, New York, NY), was inserted under the renal 
capsule in the renal cortical interstitium.  The dialysis catheter was perfused at a rate of 2 µl/min 
(see in situ dialysis methods below).  At the completion of the surgery, the rat received a 1.0 ml 
bolus of 6% heat-inactivated bovine serum albumin (BSA, Sigma, St. Louis, MO).  Any blood 
withdrawn was replaced with an equal volume bolus of 6% BSA i.v.  Rats were allowed to 
recover from the surgery for 1 hour.  Before the commencement of experimental manipulations, 
blood for basal PRA, PTH and plasma Ca were withdrawn at a volume of 300 µl each.  Rats 
were subjected to various experimental manipulations (listed below) for 90 minutes before blood 
for PRA, PTH and plasma Ca were withdrawn again.  Rats were then euthanized via bilateral 
pneumothorax and aortic transection.  The left kidney was removed for the inspection of any 
anatomical abnormalities, including ischemia, swelling and hydronephrosis.  Rats with visible 
visceral trauma were excluded from analyses.  All procedures were approved by the Henry Ford 
Health System IACUC committee, which is AAALAC approved, and adhere to the guiding 
principles in the care and use of experimental animals in accordance with the National Institutes 
of Health (NIH) guidelines. 
In situ microdialysis: Our methods of in situ microdialysis are based on the work of 
R.D. Bukoski.48  During each experimental period, 3 sequential infusions of salines with 
different concentrations of Ca were pumped through the dialysis tubing at a rate of 2 l/min.  
These salines consisted of 0.9% NaCl with varying concentrations of Ca (0.3 mmol/L, 1.0 
mmol/L, 2.2 mmol/L).  Each saline was infused through the dialysis tubing over 30 minutes.  
Only the effluent during the last 20 minutes was collected, in order to allow for the clearing of 
29 
 
the dead space in the tubing.   
The concentration of Ca for infusions and their paired effluent collections were measured 
using a NOVA-8 (NOVA Biomedical, Waltham, MA) electrolyte analyzer.  To determine the 
concentration of Ca in the cortical interstitium, the concentration of Ca in the infused saline and 
its paired effluent were plotted on a graph, as previously described.48  The Ca concentration 
infused was plotted on the X-axis and the paired difference between the effluent Ca 
concentration and the infusion Ca concentration was plotted on the Y-axis.  A line of best fit was 
generated, and the X-intercept (or point of zero flux) determined the interstitial Ca 
concentration.48  Based on preliminary data, we know that our dialysis solutions do no come into 
complete equilibrium with the cortical interstitium, as a continuous infusion of a constant 
concentration of Ca through the dialysis tubing does not yield the concentration of Ca in the 
cortical interstitium.  Thus, the entire validity of this technique is based on its ability to measure 
the flux of Ca that occurs with an infused solution.  
Parathyroidectomy (PTX):   
Parathyroidectomies were performed as described previously,3 with the exception that 
rats were used for in vivo protocols 48-72 hrs after the completion of the surgery.  PTX rats were 
placed on the 0.05% NaCl diet for 7-8 days prior to the PTX surgery, identical to rats in the other 
protocols, and were maintained on 0.05% NaCl diet for the 48-72 hr recovery period prior to any 
acute experimentation.  PTX was confirmed by undetectable plasma PTH levels. 
Plasma Renin Activity (PRA):   
PRA was analyzed from 300 μl of femoral venous blood.  Blood was centrifuged at 
16000 x g for 6 min at 4º C and the plasma was aspirated and stored at -20° C until PRA was 
determined.  PRA was analyzed by generation of angiotensin I (Ang I/ hr/min) using a Gamma 
Coat RIA kit (DiaSorin, Stillwater, MN) according to the manufacturer’s instructions. 
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Plasma parathyroid hormone (PTH) and ionized Ca:   
Measurements of plasma PTH and Ca were performed on femoral venous blood samples. 
Plasma PTH was measured using a commercial rat PTH immunoassay kit (Alpco Diagnostics, 
Salem, NH) according to the manufacturer’s instructions.  Plasma ionized Ca was measured 
using a NOVA-8 electrolyte analyzer (Nova Biomedical, Waltham, MA). 
Real-Time Quantitative RT-PCR: 
Real time RT-PCR for TRPV5 was performed by quantitative real-time RT-PCR using a 
SYBR green method. Custom rat-specific primers from TIB Molbiol (Adelphia, NJ) were used 
for all PCR reactions.  The primer sequences for TRPV5 are; forward: 5`-tgtgagccatttgtaggtcag-
3`, reverse: 5`-gaggttgtgggaacttcga-3`.  The primer sequences for claudin-16 are; forward: 5`-
agtcaatcgcattccagct-3`, reverse:5`-gagtcatcagcgttcaccat-3`. Real time RT-PCR was performed as 
follows: 1 μg of DNAse-treated total RNA sample was reverse transcribed using random primers 
and Omniscript reverse transcriptase (Qiagen, Valencia, CA) in a total volume of 20 µl for 1 hr 
at 37 °C followed by an inactivation step of 95 °C for 5 min.  2 µl of the reverse transcription 
reaction was then amplified in a Roche version 2.0 lightcycler PCR instrument (Roche, 
Indianapolis, IN) using SYBR green dye (SA Biosciences, Frederick, MD) and specific primers. 
Reactions were set up in a final volume of 20 μl, which contained 2 μl of  sample, 1 μM each of 
both the primers and 10 μl of 2x SYBR green PCR mix.  After an initial “hot start” at 95◦C for 10 
min, amplification occurred by denaturation at 95◦C for 15s, annealing at 58◦C for 45 sec, and 
extension at 72◦C for 1 min for a total of 30-40 cycles.  At the end of PCR cycling, melting curve 
analyses were performed.  A relative quantitation method [ΔΔCt]76 was used to evaluate 
expression of each gene. RT-PCR of GAPDH was used for normalization of all data. 
Statistics:  
Single changes from baseline to post-treatment were analyzed using a Student’s paired t-
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test.  Repeated changes from baseline to post-treatment were analyzed using a One-way, 
Repeated-Measures ANOVA with a Student-Newman-Keuls test for post-hoc analyses. 
Intergroup analyses were performed using a One-way ANOVA with a Student-Newman-Keuls 
test for post-hoc analyses.  Values p < 0.05 were considered statistically significant. All data are 
presented as mean ± 1 SEM.  For the purpose of simplicity, a single asterisk is used to denote 
statistical significance in figures, regardless of p-value.  Actual p-values are provided in the text. 
In vivo protocols: 
Protocol 1: NaCl Control:  (n=16) Rats were instrumented as described in the acute in 
vivo preparation section.  Rats received a control 0.9% NaCl i.v. infusion for the duration of the 
experiment. 
Protocol 2: High-Ca:  (n=17) Rats received an i.v. infusion of 0.3 mg Ca/kg 
bodyweight/min (dissolved in 0.9% NaCl, pH 7.4) over the duration of the experimental period.  
Calcium lactate pentahydrate (Sigma, St. Louis, MO) was the Ca salt used for the infusion to 
avoid increasing plasma chloride. 
Protocol 3a: High-Ca infusion+CaSR inhibition (Ronacaleret): (n=8) The calcilytic 
Ronacaleret was used to inhibit the CaSR.  Ronacaleret has a half-life of 4-5 hours in vivo.62  
Ronacaleret was generously provided by  GlaxoSmithKline, Molecular Discovery Research, 
Research Triangle Park, N.C.  Rats received the same high-Ca infusion as above, but also 
received the CaSR antagonist Ronacaleret.  Ronacaleret was given as a 1 mg/kg bodyweight i.v. 
bolus in 300 µl 0.9% NaCl every 30 minutes, commencing with the beginning of the high-Ca 
infusion.  As such, each rat received three 1 mg/kg doses of Ronacaleret during the experiment.   
Protocol 3b:  Ronacaleret control: (n=5) Rats were maintained on 0.05% NaCl chow for 
10 days before being anesthetized and instrumented identically to rats from the High-Ca in vivo 
protocols.  Rats were given a bolus of 1 mg/kg i.v.  Ronacaleret after the removal of blood for 
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basal PRA, plasma PTH and Ca measurements.  Blood for PRA, PTH and plasma Ca 
measurements were taken again 30 minutes post-Ronacaleret. 
Protocol 4a: High-Ca+parathyroidectomy (PTX): (n=8) PTX was performed as 
described previously.3  Rats were used 48-72 hours post-PTX for acute protocols.  Rats received 
the same high-Ca infusion as protocol 2, as described above. 
Protocol 4b: Extended High-Ca+parathyroidectomy (PTX): (n=4)  In 4 PTX rats from 
protocol 4a we continued the high-Ca i.v. infusion for an additional 90 minutes after the removal 
of blood for the measurement of experimental PRA, Ca and PTH values.  During this additional 
90 minute i.v. infusion, renal cortical interstitial Ca was measured again.  At the end of the 
additional 90 minute i.v. infusion, blood was withdrawn for a third determination of PRA, 
plasma Ca and plasma PTH. 
Protocol 5: High-Ca +PTH replacement infusion: (n=8) After the withdrawal of blood 
for the determination of basal PRA, plasma PTH and Ca, rats received a 200 ng/kg i.v. bolus of 
rat PTH 1-84 (Bachem, Torrance, CA) delivered in a 300 µl bolus of 0.9% saline.  During the 
i.v. high-Ca infusion, rats were concomitantly infused with 20 ng/kg/min of rat PTH 1-84, i.v.  
This was done to test whether acute changes in PTH were affecting the changes in PRA we saw 
with our high-Ca infusion, since plasma PTH levels dropped significantly in protocol 2.  These 
rats were parathyroid-intact, not PTX.   
Protocol 6: Effect of PTX on TRPV5 mRNA:  PTX (n=3) or sham (n=4) rats were 
anesthetized with Inactin (125mg/kg) 72 hours after recovering from their respective surgeries.  
The right femoral artery was catheterized and 1 ml of blood was withdrawn for plasma Ca and 
PTH quantification.  The left kidney was exposed via a mid-ventral incision, excised and 
decapsulated before cortical tissue was harvested on an ice-cold Lucite block.  Cortical tissue 
was minced in ice-cold Tri-Reagent (Molecular Research Center, Inc., Cincinnati, OH) before 
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being centrifugated at 12,000 g for 10 min at 4º C.  The supernatant was collected and snap 
frozen in liquid nitrogen and stored at -80º C until extraction of RNA. 
RESULTS 
In vivo protocols:  
Protocol 1: NaCl Control: Time controls were run without any change in Ca delivery. 
Data for protocol 1 are summarized in Figure 5, Figure 6 and Table 1. The control i.v. NaCl 
infusion had no effect on PRA, plasma Ca, plasma PTH or MAP.  Renal cortical interstitial Ca 
was 1.25±0.05 mmol/L. 
Figure 5: The effects of CaSR, PTX 
and acute PTH replacement on Ca-
mediated PRA inhibition.  Increasing 
plasma Ca decreased PRA by 37%. 
High plasma Ca did not decrease PRA 
in the presence of CaSR inhibition 
(Ronacaleret) or in PTX rats.  Increasing 
plasma Ca decreased PRA by 58% in 
rats receiving acute PTH replacement. * 
= p<0.05.  See text for specific p-values.  




Figure 6: The effects of high plasma Ca 
on renal cortical interstitial Ca. 
Increasing plasma Ca increased renal 
cortical interstitial Ca 38% above i.v. 
NaCl control values. Renal cortical 
interstitial Ca was also increased by 47% 
in the presence of high plasma Ca and 
CaSR antagonism (Ronacaleret) 
compared to NaCl controls. Renal 
cortical interstitial Ca in PTX rats 
receiving the i.v. high-Ca infusion did 
not differ from i.v. NaCl controls, even 
in the presence of the extended i.v. high-
Ca infusion. Renal cortical interstitial Ca was elevated 58% over i.v. NaCl control values in rats 
that received the i.v. high-Ca infusion with PTH replacement. * = p<0.05 versus NaCl control. 







































22.8±4.3 21.6±3.6 1.36±0.03 1.77±0.09* 80.4±19.9 34.1±23.6 97 ±2 108±2* 
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39.1±10.9 16.3±3.2* 1.19±0.05 1.81±0.10* 161.4±54.8 542.8±250.9 112±3 128±4* 
Rats were maintained on a low-NaCl diet for 10 days prior to being anesthetized and administered the I.V. 
treatment denoted in the column on the left. * = p<0.05 versus paired basal value.  # = p<0.05 versus basal i.v. 
high-Ca value.  ^ = p<0.05 versus i.v. high-Ca infusion + PTX. See text for specific p-values. Data are 
presented as mean ± 1 SEM. 
Protocol 2: High-Ca infusion:  The effect of hypercalcemia was tested by increasing the 
concentration of Ca infused into the circulation.  The i.v. high-Ca infusion significantly 
decreased PRA by 37% (p<0.001, Figure 5, Table 1).  Plasma Ca significantly increased 
(p<0.001), while plasma PTH significantly decreased (p<0.001, Table 1).  Furthermore, the i.v. 
high-Ca infusion significantly increased MAP (p<0.001, Table 1).  Renal cortical interstitial Ca 
was significantly elevated compared to the rats treated with the control i.v. infusion (1.73±0.06 
mmol/L, p<0.001, Figure 6). 
Protocol 3a: High-Ca +CaSR inhibition (Ronacaleret):  To determine if the response to 
hypercalcemia was mediated by the CaSR, we used the calcilytic Ronacaleret to block the CaSR.   
PRA did not change from basal levels in rats that received the i.v. high-Ca infusion and 
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Ronacaleret (Figure 5 and Table 1).  Plasma Ca significantly increased (p<0.01).  However, 
plasma PTH did not significantly decrease from basal levels, suggesting that the administration 
of Ronacaleret was effective at inhibiting the parathyroid gland CaSR (Table 1).  As before, 
MAP increased in the presence of the i.v. high-Ca infusion and Ronacaleret (p<0.001, Table 1), 
and renal cortical interstitial Ca was elevated compared to the NaCl control i.v. infusion 
(1.84±0.18 mmol/L, p<0.01, Figure 6.). 
Protocol 3b:  Ronacaleret control:  To determine any effect of the CaSR blocker alone, 
we ran time controls without hypercalcemia.  Based on preliminary data, 1 mg/kg Ronacaleret 
had no effect on PRA or PTH 30 min after treatment.  Plasma Ca increased 30 minutes after 
Ronacaleret administration (p<0.01, Table 1) indicating the administration of Ronacaleret was 
successful. 
Protocol 4a: High-Ca+parathyroidectomy (PTX):  To determine the role of PTH in the 
hypercalcemia-mediated inhibition of PRA, we repeated our i.v. high-Ca infusion in PTX rats.  
Basal plasma Ca was decreased in PTX rats (p<0.001).  When receiving the i.v. high-Ca 
infusion, PRA did not significantly decrease (Figure 5, Table 1), while plasma Ca significantly 
increased (p<0.001), although the final plasma Ca was less than other groups receiving the high-
Ca infusion (p<0.01).  Furthermore, MAP increased significantly (p<0.001).  Renal cortical 
interstitial Ca was not significantly different than the control NaCl rats (1.01±0.11 mmol/L, 
Figure 6). 
Protocol 4b: Extended High-Ca+parathyroidectomy (PTX):  Because the i.v. high-Ca 
infusion did not sufficiently increase plasma Ca in PTX rats (protocol 4a), we continued the 
infusion for an additional 90 minutes in 4 PTX rats to determine if further increasing plasma Ca 
could decrease PRA.  As summarized in Table 1, plasma Ca increased further (p<0.05).  PRA 
remained unaffected by the extended i.v. high-Ca infusion (Figure 5, Table 1).  MAP was still 
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elevated compared to control values (p<0.05).  As before, renal cortical interstitial Ca remained 
low and unchanged, even in the presence of further elevated plasma Ca (1.27±0.07 mmol/L, 
Figure 6).    
Protocol 5: High-Ca +PTH replacement infusion:  Acute hypercalcemia decreases PTH, 
and PTH may stimulate renin secretion.42,66  As such, we tested whether the decrease in PRA 
from acute hypercalcemia was due to the acute decrease in plasma PTH.  To test this, we infused 
PTH with the i.v. high-Ca infusion in parathyroid-intact rats.  PRA significantly decreased when 
rats were infused with both i.v. high-Ca and PTH (p<0.05, Figure 5, Table 1).  Both plasma Ca 
(p<0.001) and MAP (p<0.001) increased, while plasma PTH levels did not significantly change 
from basal levels (Table 1).  Renal cortical interstitial Ca was increased compared to rats 
receiving the i.v. NaCl control infusion (1.98±0.38 mmol/L, p<0.01, Figure 6).  Our data exclude 
the possibility that acute reductions in plasma PTH by the high-Ca infusion are directly causing 
the decrease in PRA. 
Protocol 6: Effect of PTX on TRPV5 mRNA:  To determine a potential cause of the 
impaired renal cortical interstitial Ca response in PTX rats to hypercalcemia, we measured the 
effects of PTX on the relative quantity mRNA of the distal tubule Ca transporter, TRPV5.  
Plasma Ca was significantly lower in PTX compared to sham-operated rats (0.78±0.03 mmol/L 
vs. 1.16±0.03 mmol/L, p<0.001).  PTH was undetectable in the PTX group and 114.73±14.6 
ng/ml in the sham-operated group (p<0.001), indicating the PTX was successful.  As seen in 
Figure 7, renal cortical TRPV5 mRNA was significantly less in PTX rats compared to sham-
operated (0.33±0.08 vs. 1.00±0.05 fold, respectively, p<0.001).  Claudin-16 mRNA did not 




Figure 7: The effect of PTX on renal 
cortical TRPV5 as measured with real-
time quantitative RT-PCR.  TRPV5 
mRNA was decreased by 67% in PTX 
rats. * = p<0.05 versus sham control. 
See text for specific p-values.  Data are 






We have shown that acutely increasing plasma Ca decreases PRA, and that inhibiting the 
CaSR completely eliminated the hypercalcemia-mediated inhibition of PRA.  PTX also 
completely eliminated the hypercalcemia-mediated decrease in PRA, even when plasma Ca was 
elevated further for an additional 90 minutes.  Noticeably, PTX totally eliminated the change in 
renal cortical interstitial Ca seen with hypercalcemia.  While the i.v. high-Ca infusion decreased 
plasma PTH, acutely replacing plasma PTH with the i.v. high-Ca infusion did not impair the 
hypercalcemic inhibition of PRA.  TRPV5 mRNA was decreased in PTX rats.  These data 
support the hypothesis that acute hypercalcemia inhibits PRA via the CaSR due to PTH-
mediated increases in renal cortical interstitial Ca through TRPV5.  These data are consistent 
with the notion of a direct inhibitory effect of Ca on the JG cell.27,53-56  
PRA is the ability of renin to generate angiotensin I from angiotensinogen endogenous to 
the plasma and is used as a marker of renin secretion.  PRA represents renin synthesized and 
secreted from the renal cortical JG cells, as PRA from bilaterally-nephrectomized animals 
decreases to undetectable levels.38,52  PRA has been shown to be inversely related to the plasma 
Ca concentration.  Similar to our results, acutely increasing the plasma Ca concentration in vivo 
decreases PRA. 40,41,74  However, a mechanism of how this occurred was unknown.  It should be 
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noted that the increase in plasma Ca seen in our protocols, as well as previous experiments 
examining renin in hypercalcemia, are supraphysiological. 40,41  However, the levels of ionized 
plasma Ca that we obtain with our i.v. high-Ca infusion (~1.8-1.9 mmol/L) are quantitatively 
similar to ionized plasma Ca levels take from patients with hypercalcemia of malignancy or 
hyperparathyroidism (1.72 mmol/L).75   
We have previously shown that JG cells in rats and mice, both in vitro and in vivo, 
contain CaSR.3,54  The CaSR is a seven-transmembrane domain receptor responsible for 
homeostatic regulation of plasma Ca.12  It was first described in the parathyroid gland where it 
acts by decreasing PTH secretion and increasing urinary Ca excretion in response to 
hypercalcemia.12  We have also reported that activation of the CaSR using a calcimimetic in vivo 
decreases PRA.3  Thus, we hypothesized that the CaSR should also mediate the inhibition of 
PRA by high plasma Ca.  To test this, we used a calcilytic antagonist of the CaSR (Ronacaleret) 
during hypercalcemia, and found that blocking the CaSR completely eliminated the inhibition of 
PRA by high plasma Ca (and elevated cortical interstitial Ca).  This result confirms that high 
plasma Ca inhibits PRA by acting on the CaSR.   
As a positive control, we also measured the effect of Ronacaleret on the hypercalcemia-
mediated inhibition of PTH.  The CaSR is also integral in regulating PTH secretion,12 and 
calcilytics block both parathyroid gland as well as JG cell CaSR. High plasma Ca negatively 
feeds back on the parathyroid chief cells to decrease plasma PTH via the CaSR.12,25  This is 
illustrated in our results, as we observed that acute hypercalcemia significantly decreased 
circulating plasma PTH, and this decrease was blunted by CaSR antagonism using Ronacaleret. 
PTH is an 84 amino acid peptide secreted from the chief cells of the parathyroid gland.  
PTH increases plasma Ca by stimulating Ca resorption from bone and also by stimulating renal 
Ca reabsorption.  PTH stimulates renal Ca transport primarily in the distal tubule by increasing 
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the expression and activation of the epithelial Ca transporter, TRPV5.19,32,33,69 To test whether 
acute hypercalcemia inhibits PRA via PTH-mediated increases in renal cortical interstitial Ca, 
we repeated the high-Ca infusion in PTX rats.  We found that acute hypercalcemia did not 
decrease PRA in PTX rats.  Furthermore, we found that renal cortical interstitial Ca did not 
increase with the i.v. high-Ca infusion in PTX rats.  However, due to a low basal plasma Ca from 
the PTX, the high-Ca infusion did not increase plasma Ca to an equivalent level seen in other 
groups receiving the i.v. high-Ca infusion.  To control for this, we extended the i.v. high-Ca 
infusion in 4 of the PTX rats in an attempt to further increase plasma and renal cortical 
interstitial Ca.  The extended high-Ca infusion increased plasma Ca levels to similar levels seen 
in other groups with hypercalcemia.  However, this extended high-Ca infusion still failed to 
either decrease PRA or increase renal cortical interstitial Ca in the PTX rats.  These data 
demonstrate that acute hypercalcemia inhibits PRA via PTH-mediated increases in renal cortical 
interstitial Ca. 
An important question raised by our experiments is:  how could a PTX impair the 
increase in renal cortical interstitial Ca in response to hypercalcemia?  PTH stimulates Ca 
reabsorption by increasing TRPV5-mediated Ca transport and TRPV5 expression.19,32,69  As 
such, we anticipated that our PTX rats could not increase their renal cortical interstitial Ca 
because of low TRPV5 expression.  To test this, we measured renal cortical TRPV5 mRNA in 
PTX rats and sham controls.  As expected, cortical TRPV5 mRNA was significantly decreased in 
PTX rats compared to sham-operated animals.  This indicates that the inability of PTX rats to 
increase renal cortical interstitial Ca in response to hypercalcemia may be in part due to 
decreased TRPV5 expression.  These data correspond with those of Bindels et al., who found 
that PTX decreases TRPV5 mRNA and protein, and the addition of PTH to primary cultures of 
distal tubule cells immediately increases TRPV5 expression and Ca transport.69  We also 
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examined the effect of PTX on the claudin-16, the thick ascending limb paracellular Ca 
reabsorption channel.  Renal cortical claudin-16 mRNA was not significantly decreased in PTX 
rats.  This suggests that the impaired renal cortical interstitial response in PTX rats is not due to 
decreased claudin-16 expression. 
We also sought to control for many possible confounding factors in our experiment. PTH 
has also been reported to stimulate PRA.42,66  It is possible that this may be due to a direct effect 
of PTH on the JG cell, as PTH receptors are found in isolated glomeruli with attached vessels.79  
As such, acute hypercalcemia could decrease PRA by acutely decreasing plasma PTH, 
decreasing the stimulatory effect of PTH on renin secretion.  To test if this was the case, we 
repeated the i.v. high-Ca infusion in parathyroid intact rats with a concomitant i.v. PTH infusion 
to keep plasma PTH from decreasing.  Even when plasma PTH was maintained at physiologic 
levels in acute hypercalcemia, PRA still decreased.  This indicates that acute hypercalcemia does 
not decrease PRA through acute decreases in PTH. 
Changes in blood pressure regulate PRA through the renal baroreceptor mechanism,65 
such that increases in blood pressure decrease PRA.  Hypercalcemia increases blood pressure,68 
ostensibly by a direct action on L-type voltage-gated Ca channels on the vascular smooth 
muscle.8  As such, we measured the effects of our high-Ca infusion on MAP.  The high-Ca 
infusion increased MAP, as expected.  However, it is unlikely that this increase in MAP affected 
PRA, as it also increased in the Ronacaleret and PTX groups, which experienced no change in 
PRA.  As such, it appears that high plasma Ca does not decrease PRA through increased MAP.  
Many experimental setups induced renal baroreceptor-mediated changes in PRA via 
instantaneous changes in perfusion pressure.  The elevation in MAP we saw with our infusions 
was a more gradual increase in MAP.4,71  Thus, we may have avoided renal baroreceptor-
mediated changes in PRA due to the rate at which MAP changed.  This is consistent with the 
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previous literature.40,71  Additionally, when we divided the change in PRA over the change in 
MAP and compared these values from our High-Ca vs. High-Ca+PTH groups, we saw no 
difference.  As an additional control, we measured the effect of Ronacaleret on basal PRA and 
found that CaSR blockade had no effect.  Thus, Ronacaleret does not stimulate PRA, per se, but 
inhibits its decline in response to hypercalcemia-mediated CaSR stimulation. 
One potential criticism of our work is that our basal PRA values are highly variable.  This 
is due to the low-NaCl diet our rats were placed on, to elevate basal PRA levels and increase the 
likelihood that we would see an inhibition of PRA by high plasma Ca.  This practice is consistent 
with previous experiments in the literature.40,41  Additionally, the basal PRA level in the rats 
receiving the i.v. high-Ca infusion (protocol 2) appears higher than other groups.  However, there 
is no statistical difference between these basal PRA levels, and furthermore, they do not affect 
our results.  When we take rats from protocol 2 with numerically identical baselines to other 
groups, the i.v. high-Ca infusion still decreases PRA from 21.2±1.6 to 12.3±1.2 ng Ang I/ml/hr 
(p<0.001, n=9).  Our findings are identical for protocol 5; when we take rats with a numerically 
identical baseline, the i.v. high-Ca infusion with PTH replacement still decreased PRA from 
24.2±4.3 to 12.7±2.8 ng Ang I/ml/hr (p<0.05, n=6).  As such, apparent, but not actual, baseline 
PRA differences do not affect our PRA results. 
In summary, our data address a 30-year old question in renal physiology: how does acute 
hypercalcemia inhibit PRA in vivo?40  The answer appears to be that hypercalcemia inhibits PRA 
by acting on the CaSR.  These data are consistent with a direct effect of Ca on the JG cell.  The 
cascade downstream of JG cell CaSR activation, involving inhibition of adenylyl cyclases and 
stimulation of phosphodiesterases, has already been described in detail.27,53-56  The chronic 
presence of PTH is necessary for the inhibition of PRA by hypercalcemia by mediating the 
increase in interstitial Ca in response to hypercalcemia via TRPV5.  Our data do not support the 
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idea that hypercalcemia decreases PRA by acutely decreasing (a renin-stimulating effect of) 
plasma PTH.  All of these data help support the growing body of evidence that the CaSR is an 
integral component in regulating renin. 
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CHAPTER 3: THE EFFECTS OF A SUBCAPSULAR CALCIUM INFUSION ON 
RENAL CORTICAL INTERSTITIAL CALCIUM AND PLASMA RENIN ACTIVITY 
ABSTRACT 
Hypercalcemia decreases plasma renin activity (PRA) by increasing renal cortical 
interstitial calcium (Ca).  It is unknown whether increased renal cortical interstitial Ca inhibits 
PRA independently of changes in plasma Ca.  We hypothesized that increased renal cortical 
interstitial Ca can inhibit PRA independently of changes in plasma Ca.  Experiments were run 
acutely in anesthetized rats.  Rats received control, intermediate Ca, or high Ca renal subcapsular 
infusions for the purpose of increasing renal cortical interstitial Ca.  Renal cortical interstitial Ca 
was measured with in situ microdialysis.  The renal cortical interstitial Ca with the control 
subcapsular infusion was 1.03±0.05 mmol/L.  Renal cortical interstitial Ca did not significantly 
differ with the intermediate Ca subcapsular infusion (2.57±0.96 mmol/L).  However, renal 
cortical interstitial Ca was significantly elevated in the High Ca subcapsular infusion compared 
to the control group (3.17±0.58 mmol/L, p<0.05).  Plasma Ca did not significantly differ 
between groups.  PRA did not significantly change with the control subcapsular infusion.  PRA 
decreased significantly with the intermediate subcapsular infusion, from 49.07±9.35 to 
31.54±7.92 ng Ang I/ml/hr (p<0.05).  PRA did not significantly change in the high Ca 
subcapsular infusion group.  Thus, contrary to our hypothesis, we were unable to consistently 
inhibit PRA by increasing renal cortical interstitial Ca independently of plasma Ca. 
INTRODUCTION 
It has been known that plasma renin activity (PRA) is decreased by elevated plasma 
calcium (Ca).40,41,74  However, how this occurs is incompletely understood.  The renin-secreting 
juxtaglomerular cells are bordered basolaterally by the renal cortical interstitium in vivo.  
Increasing plasma Ca increases the concentration of Ca in the renal cortical interstitium.  Thus, 
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increasing plasma Ca could inhibit renin secretion by increasing renal cortical interstitial Ca.  In 
support of this, we have previously shown that hypercalcemia both decreases PRA and increases 
renal cortical interstitial Ca (see Chapter 2).  However, this method of increasing renal cortical 
interstitial Ca required elevated plasma Ca.  It is unknown if increasing renal cortical interstitial 
Ca independently of plasma Ca can decrease renin secretion.   
To this end, we hypothesized that increasing renal cortical interstitial Ca independently of 
plasma Ca would decrease PRA.  To test this hypothesis, we employed a subcapsular renal Ca 
infusion and measured the effects on plasma renin activity (PRA). 
MATHERIALS & METHODS 
In vivo prep:   
Male Sprague-Dawley rats (approximately 200 g, Charles River Laboratory, Wilmington, 
MA) were placed on a low-salt diet (0.05% NaCl) for 2 weeks.  After 2 weeks, they were 
anesthetized using thiobutabarbital, 125 mg/kg body weight I.P. (Inactin, Sigma, St. Louis, MO) 
and placed on a heating pad to maintain constant body temperature.  A tracheotomy was 
performed with PE-240 tubing to allow spontaneous breathing of room air.  The femoral vein 
was catheterized with PE-50 tubing for infusion of 10 μl/min 0.9% NaCl.  The femoral artery 
was catheterized with PE-50 tubing attached to a Statham pressure transducer (Viggo-
Spectramed, Oxnard, CA), calibrated using a “Traceable” electronic manometer (Fisher 
Scientific, Pittsburgh, PA), and connected through an iWorx 118 A to D Signal Processor to a 
computer using iWorx Labscribe 2.065 data acquisition software (iWorx, Dover, NH) for 
continuous monitoring of mean arterial pressure (MAP).  Renal blood flow (RBF) was measured 
using a 1.5R Transonic Flowprobe (Transonic Systems Inc, Ithaca, NY) placed over the left renal 
artery.  The probe was connected to a T206 small animal blood flow meter (Transonic Systems 
Inc, Ithaca, NY) and to the iWorx data acquisition software.  A microdialysis probe consisting of 
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a single 1-cm strand of dialysis tubing (Hemoflow F8, Fresenius Medical Care, Lexington, MA), 
ligated to 2 pieces of PE-20 tubing, was inserted under the renal capsule, with the distal PE 
tubing protruding from the capsule for the collection of the effluent saline.  For the volume 
expansion and infusion of the renal cortex, 2 separate pieces of PE-20 tubing were inserted under 
the renal capsule.  All perforations of the renal capsule were sealed with Vetbond (3M, St. Paul, 
MN).  Renal venous blood was sampled with a 25-gauge needle, bent to 90 degrees, attached to 
PE-50 tubing connected to a 1-ml syringe filled with heparinized saline.  After surgery, the rats 
received a supplemental bolus of 1.0 ml of 6% heat-inactivated bovine serum albumin (BSA, 
Sigma, St. Louis, MO) in normal saline and were allowed to recover for 90 min.  All blood 
samples taken were 300 μL in volume, and were replaced with an equal volume of 6% BSA.  
When the experiments were completed, the rats were euthanized by pneumothorax and aortic 
transection, and the kidneys decapsulated, excised, weighed and inspected for anatomical 
abnormalities. 
Plasma Renin Activity (PRA):   
PRA was analyzed from 300 μl of femoral venous blood.  Blood was centrifuged at 
16000 x g for 6 min at 4º C and the plasma was aspirated and stored at -20° C until PRA was 
determined.  PRA was analyzed by generation of angiotensin I (Ang I/ hr/min) using a Gamma 
Coat RIA kit (DiaSorin, Stillwater, MN) according to the manufacturer’s instructions. 
Interstitial dialysis:   
To measure interstitial Ca during the subcapsular infusions, 3 different isotonic salines 
(0.3 mmol/L Ca, 1.0 mmol/L Ca, and 10.0 mmol/L Ca) are perfused through the dialysis tubing 
at a rate of 2 μl/min for 30 min each.  Only the last 20 min of each effluent are collected, as the 
first 10 minutes allow for the dead space to clear.  Once collected, the concentration of Ca in 
each is measured using an NOVA-8 electrolyte analyzer (Nova Biomedical, Waltham, MA).  To 
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determine the interstitial Ca concentration, a graph is generated with the infused concentrations 
of Ca on the X-axis, and the difference between the effluent Ca (out) minus the paired infused Ca 
(in) on the Y-axis.  Using these three points, linear regression is used to make a line of best fit.  
The point at which the line crosses the X-axis (Ca out-Ca in = 0) is the value of the interstitial Ca 
concentration. 
Plasma Ca:   
Blood for plasma Ca measurements were taken at the end of the experiment.  Plasma Ca 
was measured with a NOVA-8 electrolyte analyzer (Nova Biomedical, Waltham, MA).   
Experimental Groups:   
Group 1:  Control Ca subcapsular infusion (n=8): After the sampling of basal RSR 
blood and plasma Ca, we injected a bolus of 250 μl of 1.2 mM Ca (CaCl2) dissolved in 0.9% 
saline, into the renal cortical interstitium through the PE-20 tubing.  After this we infused the 
renal cortical interstitium with 1.2 mM Ca at 10 μl/min for 15 min.  When this was completed, 
we infused the cortical interstitium with 1.2 mM Ca at 5 μl/min for the remainder of the 
experiment. 
Group 2:  Intermediate Ca subcapsular infusion (n=6):  This protocol was run identically 
to Group 1, except 12.5 mM Ca was used as the subcpasular infusate. 
Group 3:  High Ca subcapsular infusion (n=7):  This protocol was run identically to 
Group 1, except 25 mM Ca was used as the subcapsular infusate. 
Statistics:   
Repeated changes from baseline to post-treatment were analyzed using a One-way, 
Repeated-Measures ANOVA with a Student-Newman-Keuls test for post-hoc analyses. 
Intergroup analyses were performed using a One-way ANOVA with a Student-Newman-Keuls 
test for post-hoc analyses.  Values p < 0.05 were considered statistically significant.  All data are 
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presented as mean ± SEM.  For the purpose of simplicity, a single asterisk is used to denote 
statistical significance in figures, regardless of p-value.  Actual p-values are provided in the text. 
RESULTS 
First, we measured the effects of our subcapsular Ca infusions on renal cortical interstitial 
Ca, using in situ microdialysis.  This was done to ensure the intermediate and high Ca 
subcapsular infusions increased renal cortical interstitial Ca.  In Figure 8, the renal cortical 
interstitial Ca was 1.03±0.05 mmol/L with the Control Ca subcapsular infusion.  The renal 
cortical interstitial Ca in the Intermediate Ca subcapsular infusion did not significantly differ 
from group 1 (2.57±0.96 mmol/L).  However, renal cortical interstitial Ca was significantly 
elevated in the High Ca subcapsular infusion compared to group 1 (3.17±0.58 mmol/L, p<0.05). 
 
 
Figure 8:  The effects of subcapsular 
Ca infusions on renal cortical 
interstitial Ca.  The intermediate-Ca 
subcapsular infusion did not increase 
renal cortical interstitial Ca compared 
to control, due to high variability.  
The high-Ca subcapsular infusion 
increased renal cortical interstitial Ca 
approximately 3-fold compared to the 




We also measured our systemic PRA values during the subcapsular infusions (Figure 9, 
Table 2).  PRA did not significantly change during the Control Ca subcapsular infusion.  PRA 
decreased during the Intermediate Ca subcapsular infusion at both 60 and 120 minutes after the 
start of the subcapsular infusion (p<0.05).  Systemic PRA did not significantly change during the 
High Ca subcapsular infusion. 
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Figure 9:  The effects of 
subcapsular Ca infusions on PRA.  
The control infusion did not 
significantly change PRA.  PRA 
decreased with the intermediate-
Ca infusion at 60 and 120 minutes 
(p<0.05), coinciding with an 
increase in MAP seen in table 2.  
PRA did not change in the high-
Ca infusion group. N=6-8. 
 
 
Table 2:  The effects of subcapsular-Ca infusions on PRA. 
 Basal Systemic PRA 
(ng Ang I/ml/hr) 
60 min Systemic PRA 
(ng Ang I/ml/hr) 
120 min Systemic PRA 
(ng Ang I/ml/hr) 
Control subcapsular 
infusion 44.09±5.18 42.75±5.86 40.27±5.16 
Intermediate- Ca 
subcapsular infusion 49.07±9.35 35.01±9.54* 31.54±7.92* 
High-Ca subcapsular 
infusion 42.02±6.05 40.35±7.47 40.22±9.05 
PRA did not significantly decrease in the control or high-Ca infusion groups.  PRA decreased in the 
intermediate-Ca group at 60 and 120 minutes (p<0.05).   
 To determine if the subcapsular Ca infusions were affecting plasma Ca, we measured 
plasma Ca at the end of our experiments (Table 3).  No significant differences existed between 
any of the subcapsular infusion groups with respect to plasma Ca levels.  Thus, we were able to 
dissociate changes in renal cortical interstitial Ca from changes in plasma Ca. 







60 min RBF 
(ml/min/gkw) 























1.21±0.04 6.01±0.58 5.33±0.63 5.80±0.85 108±3 104±4 106±4 
Plasma Ca did not significantly differ between groups.  Subcapsular infusions did not affect RBF.  MAP 
increased slightly, but significantly, in the intermediate-Ca subcapsular infusion (p<0.05).  MAP did not 
change in the other groups. 
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 We also measured the effects of the subcapsular renal infusions on renal blood flow 
(RBF) and mean arterial pressure (MAP).  As seen in Table 3, RBF did not significantly change 
in any of the groups receiving a subcapsular infusion.  MAP did not significantly change in 
either the Control or High Ca renal subcapsular infusions.  However, MAP did increase in the 
Intermediate Ca renal subcapsular infusion at both 60 and 120 minutes after the commencement 
of the subcapsular infusion (p<0.05). 
DISCUSSION 
The aim of our experiments was to decrease PRA by increasing renal cortical interstitial 
Ca, independently of plasma Ca, using a renal subcapsular infusion.  Our results illustrate that 
our high-Ca subcapsular increased renal cortical interstitial Ca.  This increase in interstitial Ca 
did not affect plasma Ca, indicating we dissociated renal cortical interstitial Ca levels from 
plasma Ca levels.  However, the increase in renal cortical interstitial Ca in the high-Ca group did 
not decrease PRA, suggesting that increasing renal cortical interstitial Ca independently of 
plasma Ca does not decrease PRA.   
However, we did notice that PRA did decrease in the intermediate-Ca infusion group.  
But, it is unlikely that the decrease in PRA we saw in this group were due to the intermediate-Ca 
subcapsular infusion, as we were unable to replicate the decrease in PRA with the high-Ca 
infusion.  As such, we could not consistently decrease PRA by increasing renal cortical 
interstitial Ca.  There were multiple problems with our experimental setup.  Infusing solutions 
into the renal cortical interstitium can increase the cortical hydrostatic pressure and potentially 
impair the diffusion of Ca across the dialysis membrane.  Additionally, we cannot ascertain 
whether Ca diffused equally across the renal cortical interstitium.  Thus, we cannot make any 




CHAPTER 4: THE EFFECTS OF CHANGING RENAL SODIUM CHLORIDE 
REABSORPTION ON RENAL CORTICAL INTERSTITIAL CALCIUM 
ABSTRACT 
Elevated thick ascending limb NaCl reabsorption inhibits plasma renin activity (PRA), 
but it is unknown how this occurs.  Elevated thick ascending limb NaCl reabsorption stimulates 
thick limb calcium (Ca) reabsorption and renal cortical interstitial Ca.  Previously, it has been 
shown that Ca inhibits PRA.  Thus, we hypothesize that increased distal NaCl delivery and 
reabsorption will increase renal cortical interstitial Ca and inhibit PRA.  To increase distal NaCl 
delivery and reabsorption, we performed the following manipulations:  Acutely, we used either 
isotonic or hypertonic, isocalcemic volume expansions in anesthetized rats and measured renal 
cortical interstitial Ca with in situ microdialysis.  Chronically, rats consumed a high NaCl diet 
for 2 weeks prior to renal cortical interstitial Ca measurement.  We acutely inhibited thick 
ascending limb NaCl reabsorption with the loop diuretic furosemide to decrease renal cortical 
interstitial Ca (and increase PRA) in anesthetized rats.  The isotonic volume expansion did not 
change renal cortical interstitial Ca from 1.44±0.11 mmol/L.  Basal renal cortical interstitial Ca 
before the hypertonic, isocalcemic volume expansion was 1.22±0.08 mmol/L and did not change 
after the volume expansion (1.20±0.07 mmol/L).  Renal cortical interstitial Ca in rats consuming 
a high-NaCl diet (1.25±0.07 mmol/L) did not significantly differ from rats consuming a normal 
NaCl diet (1.23±0.08 mmol/L).  Inhibiting thick limb NaCl transport with furosemide decreased 
renal cortical interstitial Ca from 1.20±0.08 mmol/L to 1.05±0.09 mmol/L (p<0.01).  However, 
renal cortical interstitial Ca also decreased in our vehicle-controls, from 1.38±0.09 mmol/L to 
1.27±0.10 mmol/L (p<0.05).  Furosemide increased PRA from 12.44±2.05 to 33.77±6.93 ng Ang 
I/ml/hr (p<0.05), while the vehicle-control had no effect.  Our data do not support our hypothesis 
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that increased distal NaCl delivery and reabsorption inhibits PRA by increasing renal cortical 
interstitial Ca. 
INTRODUCTION 
Renin is the rate-limiting enzyme of the renin-angiotensin system and is secreted from 
the juxtaglomerular cells in the afferent arteriole of the kidney.  Renin secretion in vivo responds 
to changes in NaCl delivery and reabsorption in the thick ascending limb of the loop of Henle.  
Specifically, decreased NaCl reabsorption stimulates and increased NaCl reabsorption inhibits 
renin secretion, respectively.28,72  While it is known the decreased NaCl reabsorption stimulates 
renin secretion via increased cyclooxygenase-2 metabolite production at the macula densa,2 it is 
unknown how increased NaCl delivery inhibits renin secretion. 
It has been reported that high-NaCl diets increase renal cortical interstitial Ca.57  NaCl 
reabsorption in the thick ascending limb stimulates concomitant calcium (Ca) reabsorption.9  
NaCl reabsorption through the thick ascending limb via the apical NaCl transporter, NKCC2, 
contributes to the lumen-positive voltage potential in the thick ascending limb.9  This lumen-
positive voltage is the driving force for Ca reabsorption through the paracellular channel, 
claudin-16.5  Thus, increased distal NaCl delivery and coupled reabsorption should increase Ca 
reabsorption and subsequently renal cortical interstitial Ca. 
Renin secretion is inhibited by elevated extracellular Ca both in vivo and in vitro.  In vivo, 
the inhibition of renin by high Ca is mediated by increases in renal cortical interstitial Ca that act 
on the calcium-sensing receptor (CaSR, see Chapter 2).  As such, it seemed likely that increased 
distal NaCl reabsorption would be accompanied by increased Ca reabsorption and therefore, 
renal cortical interstitial Ca.  With these considerations, we hypothesized that increased distal 
NaCl reabsorption would increase renal cortical interstitial Ca which would inhibit plasma renin 
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activity (PRA).   
To test this hypothesis, we increased distal NaCl delivery with an acute volume 
expansion or chronically with increased dietary NaCl and measured the effects on renal cortical 
interstitial Ca.  Conversely, we also inhibited NaCl reabsorption with the loop diuretic 
furosemide, and anticipated that it would both decrease renal cortical interstitial Ca and increase 
PRA. 
MATERIALS AND METHODS 
Acute in vivo prep:   
Male Sprague-Dawley rats (approximately 200 g, Charles River Laboratory, Wilmington, 
MA) were anesthetized using thiobutabarbital, 125 mg/kg body weight I.P. (Inactin, Sigma, St. 
Louis, MO) and placed on a heating pad to maintain constant body temperature.  A tracheotomy 
was performed with PE-240 tubing to allow spontaneous breathing of room air.  The femoral 
vein was catheterized with PE-50 tubing for infusion of 10 μl/min 0.9% NaCl.  The femoral 
artery was catheterized with PE-50 tubing attached to a Statham pressure transducer (Viggo-
Spectramed, Oxnard, CA), calibrated using a “Traceable” electronic manometer (Fisher 
Scientific, Pittsburgh, PA), and connected through an iWorx 118 A to D Signal Processor to a 
computer using iWorx Labscribe 2.065 data acquisition software (iWorx, Dover, NH) for 
continuous monitoring of mean arterial pressure (MAP).  A microdialysis probe consisting of a 
single 1-cm strand of dialysis tubing (Hemoflow F8, Fresenius Medical Care, Lexington, MA), 
ligated to 2 pieces of PE-20 tubing, was inserted under the renal capsule, with the distal PE 
tubing protruding from the capsule for the collection of the effluent saline.  After surgery, the 
rats received a supplemental bolus of 1.0 ml of 6% heat-inactivated bovine serum albumin (BSA, 
Sigma, St. Louis, MO) in normal saline and were allowed to recover for 90 min. All blood 
53 
 
samples taken were 300 μL in volume, and were replaced with an equal volume of 6% BSA.  
Urine was collected by voiding the bladder with a 25-gauge needle attached to a 1 ml syringe.  
When the experiments were completed, the rats were euthanized by pneumothorax and aortic 
transection, and the kidneys decapsulated, excised, weighed and inspected for anatomical 
abnormalities. 
Interstitial dialysis:   
To measure interstitial Ca during the subcapsular infusions, 3 different isotonic salines 
(0.3 mmol/L Ca, 1.0 mmol/L Ca, and 2.0 mmol/L Ca) are perfused through at a rate of 2 μl/min 
for 30 min each through the dialysis tubing.  Only the last 20 min of each effluent are collected, 
as the first 10 minutes allow for the dead space to clear.  Once collected, the concentration of Ca 
in each is measured using an NOVA-8 electrolyte analyzer (Nova Biomedical, Waltham, MA).  
To determine the interstitial Ca concentration, a graph is generated with the infused 
concentrations of Ca on the X-axis, and the difference between the effluent Ca (out) minus the 
paired infused Ca (in) on the Y-axis.  Using these three points, linear regression is used to make 
a line of best fit.  The point at which the line crosses the X-axis (Ca out-Ca in = 0) is the value of 
the interstitial Ca concentration. 
Plasma Renin Activity (PRA):  
PRA was analyzed from 300 μl of femoral venous blood.  Blood was centrifuged at 
16000 x g for 6 min at 4º C and the plasma was aspirated and stored at -20° C until PRA was 
determined.  PRA was analyzed by generation of angiotensin I (Ang I/ hr/min) using a Gamma 
Coat RIA kit (DiaSorin, Stillwater, MN) according to the manufacturer’s instructions. 
Statistics:  
Single changes from baseline to post-treatment were analyzed using a Student’s paired t-
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test.  Intergroup analyses were performed using a Student’s t-test.  Values p < 0.05 were 
considered statistically significant.  All data are presented as mean ± 1 SEM.  For the purpose of 
simplicity, a single asterisk is used to denote statistical significance in figures, regardless of p-
value.  Actual p-values are provided in the text. 
Experimental Groups: 
Set 1: Acute Volume Expansion  
Group 1: isotonic saline volume expansion (n=3):  Rats were instrumented as described 
above.  A basal renal cortical interstitial Ca measurement was made prior to initiating a 3% 
bodyweight, 0.9% NaCl volume expansion via the femoral vein catheter, delivered over 30 
minutes.  Immediately after the volume expansion, renal cortical interstitial Ca was measured 
again. 
Group 2: hypertonic, isocalcemic saline volume expansion (n=12):  This protocol was 
run identically to group 1, with the exception that the rats received a 1.5% bodyweight, 1.8% 
NaCl volume expansion containing 1.2 mmol/L Ca. 
Set 2: Chronic high NaCl diet. 
Group 3: Normal NaCl diet (n=5):  Rats were maintained on a normal NaCl diet (0.49%) 
for 2 weeks prior to being instrumented for renal cortical interstitial Ca measurements.  3 Rats 
were also placed in metabolic caging for the measurement of 24-hour urinary volume at various 
time points prior to renal cortical interstitial Ca measurement 
Group 4: High NaCl diet (n=4):  Rats were maintained on a high NaCl diet (3.2%) for 2 
weeks prior to being instrumented for renal cortical interstitial Ca measurements.  3 Rats were 
also placed in metabolic caging for the measurement of 24-hour urinary volume at various time 
points prior to renal cortical Ca measurement. 
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Figure 10:  The effect of an acute, hypertonic, 
isocalcemic volume expansion (V.E.) on renal 
cortical interstitial Ca.  The volume expansion did 






Set 3: Inhibition of thick ascending limb NaCl reabsorption with furosemide. 
Group 5:  control (n=4):  Rats were instrumented as described in the in vivo prep section.  
Basal PRA, renal cortical interstitial Ca and urinary volume measurements were taken before 
giving a 500 µl bolus of 0.9% NaCl, i.v.  Renal cortical interstitial Ca was then measured after 
the i.v. bolus and PRA and urinary volume were measured at the end of the experiment.    
Group 6:  furosemide (n=8):  Experiments were run identically to group 3, except that 
rats received 5 mg/kg furosemide delivered in a 500 µl bolus of 0.9% NaCl, i.v. 
RESULTS 
Set 1: Acute Volume Expansion  
Group 1: isotonic saline volume expansion:  Basal renal cortical interstitial Ca was 
1.44±0.11 mmol/L.  The 3% bodyweight volume expansion did not significantly change renal 
cortical interstitial Ca (1.18±0.03 mmol/L). 
Group 2: hypertonic, isocalcemic saline volume expansion:  Basal renal cortical 
interstitial Ca was 1.22±0.08 mmol/L.  As seen in Figure 10, renal cortical interstitial Ca did not 
significantly differ after the hypertonic, isocalcemic volume expansion (1.20±0.07 mmol/L). 
Set 2: Chronic high NaCl diet. 
Group 3: Normal NaCl diet:  Renal cortical interstitial Ca was 1.23±0.08 mmol/L after 2 
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weeks on a normal NaCl diet.  The rats in this group produced 10.0±2.9 ml of urine in 24 hrs, 
and rats in this group excreted 0.75±0.33 mmoles Na /24 hrs. 
Group 4: High NaCl diet:  Renal cortical interstitial Ca in the high dietary NaCl group 
was 1.25±0.07 mmol/L, and as seen in Figure 11, this did not differ significantly from the rats on 
the normal NaCl diet (group 3).  The rats on the high NaCl diet urinated significantly more than 
rats on the normal NaCl diet (73.3±9.7 ml of urine in 24 hrs, p<0.01), and excreted more Na 
(17.7±2.6 mmoles Na/24 hrs, p<0.01). 
Figure 11:  The effect a chronic, high NaCl 
diet (3.2%) on renal cortical interstitial Ca.  
Rats were maintained on control or high NaCl 
diets for 2 weeks prior to renal cortical 
interstitial Ca measurement.  Renal cortical 
interstitial Ca in the high NaCl diet group did 










Set 3: Inhibition of thick ascending limb NaCl reabsorption with furosemide. 
Group 5:  control:  Basal renal cortical interstitial Ca was 1.38±0.09 mmol/L and 
decreased slightly but significantly with the control bolus to 1.27±0.10 mmol/L (Figure 12, 
p<0.05).  Basal PRA was 18.86±2.88 ng Ang I/ml/hr and did not change significantly with the 
saline control bolus (14.57±5.00 ng Ang I/ml/hr).  Urinary volume prior to the bolus (0.64±0.09 
ml) did not significantly differ from that after the control bolus (0.84±0.21 ml). 
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Figure 12:  The effect of furosemide on 
renal cortical interstitial Ca.  Renal cortical 
interstitial Ca was measured over 90 
minutes, both before and immediately after 
an i.v. control bolus or a bolus of 
furosemide.  Basal interstitial Ca is the left 
bar in each group, while the experimental 
value is on the right.  The control i.v. bolus 
slightly, but significantly, decreased renal 
cortical interstitial Ca.  Furosemide also 
significantly decreased renal cortical 
interstitial Ca.  * = p<0.05 vs. basal.  N=4-
8. 
 
Group 6:  furosemide:  Basal renal cortical interstitial Ca was 1.20±0.08 mmol/L and 
decreased significantly with furosemide to 1.05±0.09 mmol/L (Figure 12, p<0.01).  Furosemide 
significantly increased PRA from 12.44±2.05 to 33.77±6.93 ng Ang I/ml/hr (Figure 13, p<0.05).  
Furosemide increased urinary volume from 0.67±0.16 to 5.60±0.96 ml during the collection 
period (p<0.05). 
Figure 13: The effect of furosemide 
on PRA.  PRA was measured at the 
end of the basal and experimental renal 
cortical interstitial Ca measurement 
periods. The basal measurement is the 
left bar of each group, and the 
experimental value is the right bar in 
each group. The control bolus had no 
effect on PRA. Furosemide 
significantly increased PRA, consistent 
with previous reports.8,9  * = p<0.05 




Based on previous reports, we anticipated that increasing distal NaCl delivery and 
reabsorption should increase renal cortical interstitial Ca.  We hypothesized that increased distal 
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NaCl reabsorption would increase renal cortical interstitial Ca which would inhibit PRA.  
However, neither the isotonic nor hypertonic, isocalcemic volume expansions increased renal 
cortical interstitial Ca.  Additionally, chronically increasing distal NaCl delivery and 
reabsorption with a high-NaCl diet did not increase renal cortical interstitial Ca.  Conversely, 
when inhibiting distal NaCl reabsorption with the loop diuretic furosemide, we saw small but 
significant decreases in renal cortical interstitial Ca.  However, we saw the same response in our 
vehicle controls.  Contrary to our hypothesis, our data show that both increased and decreased 
NaCl delivery and reabsorption in the thick ascending limb were unable to significantly change 
renal cortical interstitial Ca.  
The most likely explanation for the discrepancy between our proposed and actual results 
relates to the changes in volume associated with changes in NaCl delivery.  Volume expansion 
inhibits Ca reabsorption.1,59  Therefore, in the acute volume expansion protocols, any stimulatory 
effect of NaCl reabsorption on renal cortical interstitial Ca may have been negated by the 
concomitant volume delivered.  A similar effect also could account for the inability of the high-
NaCl diet to increase renal cortical interstitial Ca.  The rats on the high-NaCl diet were likely 
volume expanded, as evidenced by their sevenfold higher urinary flow rate. 
Our results with the high NaCl diet contrast with those from Bukoski’s group, who 
showed a significant increase in renal cortical interstitial Ca in response to high dietary NaCl.57  
There are differences in the two studies’ protocols.  We employed a 3.2% NaCl diet, which has 
6.5-fold greater NaCl than the normal NaCl diet.  Na excretion increased 10-fold on this diet, 
suggesting the high-NaCl diet was being ingested.  However, in the Bukoski study, the high-
NaCl diet contained twentyfold more NaCl than controls, but they only excreted twice as much 
NaCl.  Bodyweights were not reported.  This suggests that the rats on the high NaCl diet in their 
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study were not consuming their high-NaCl diet, and the stress of reduced caloric intake may have 
affected renal cortical interstitial Ca.   
Finally, we found that inhibiting thick ascending limb NaCl reabsorption with furosemide 
slightly but significantly decreased renal cortical interstitial Ca.  However, in these studies, our 
vehicle controls demonstrated a similar effect, suggesting that the decrease in renal cortical 
interstitial Ca was not furosemide-specific.  PRA increased with furosemide, indicating that its 
administration was successful.  Furosemide is a well-characterized stimulus for renin 
secretion.4,70  The inability of furosemide to decrease renal cortical interstitial Ca was once again 
likely due to a concomitant effect on circulating volume.  As a potent diuretic, furosemide 
significantly increased the urinary flow rate, possibly causing acute volume depletion.  It is well 
known that volume contraction caused by diuretics can increase proximal tubule Ca 
reabsorption,51 which would negate any inhibitory effect of furosemide on Ca reabsorption.  
Thus, while furosemide stimulated renin secretion, its pathway appears to be independent of 
decreased renal cortical interstitial Ca. 
In conclusion, our data demonstrate that acute and chronic changes in distal NaCl 
delivery and reabsorption do not affect renal cortical interstitial Ca, possibly due to the 
confounding effects of volume associated with the NaCl loads delivered.  This raises the 
question, how does high NaCl inhibit renin?  A likely answer has been provided the work of 
Schnermann et al., suggesting that the inhibition of PRA by high-NaCl is mediated by adenosine 
release from the macula densa.39  Adenosine is a metabolic by-product of NaCl reabsorption in 
the thick limb and macula densa, and has been shown to inhibit renin secretion.39,49  Taken 
together, these data suggest that, contrary to our hypothesis, increased NaCl reabsorption in the 





 In conclusion, the sum of our data show that the CaSR is expressed in the renin-
containing JG cells in vivo, and the stimulating the CaSR acutely inhibits PRA.  We have also 
shown that hypercalcemia inhibits PRA via the CaSR and PTH-mediated increases in renal 
cortical interstitial Ca via TRPV5.  Directly increasing renal cortical interstitial Ca independently 
of the plasma does not consistently affect PRA.  Lastly, changes in PRA caused by changes in 
renal NaCl delivery and reabsorption are not due to renal cortical interstitial Ca.  Thus, our data 
support our hypothesis that hypercalcemia inhibits PRA via PTH-mediated increases in renal 
cortical interstitial Ca that act on the CaSR. 
Our in vivo data, and previous in vitro data, provide a novel, unified hypothesis for how 
acute hypercalcemia inhibits renin release from the JG cells.  PTH is necessary for the TRPV5-
mediated increase in renal cortical interstitial Ca in response to hypercalcemia.  Increased renal 
cortical interstitial Ca stimulates the JG-cell expressed CaSR.  This increases JG cell intracellular 
Ca, which decreases cellular cAMP via decreased adenylate cyclase activity and increased 
phosphodiesterase activity.  Since cAMP is the major stimulatory second messenger for renin 
release, this Ca-mediated decrease in cAMP retards renin secretion.  The data from this thesis are 
crucial, because they demonstrate that high plasma Ca inhibits renin both in vitro and in vivo by 
similar mechanisms. 
The last major question to address with our research is, how does this relate to 
pathophysiology?  While we have used high levels of hypercalcemia to amplify our results, it is 
likely that more subtle interactions between Ca reabsorption, interstitial Ca concentrations, and 
cAMP-mediated renin secretion take place constantly at lesser changes levels of Ca. While 
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chronic hypercalcemia from paraneoplastic syndromes or tumor metastases is more likely to be 
seen in the clinic, there are many such instances in which patients may be subject to acute 
hypercalcemia as well.  Transient hypercalcemia can occur in acute renal failure, hemodialysis, 
rhabdomyolysis, thyrotoxicosis, milk-alkali syndrome, or Williams syndrome.  Interestingly, it 
has been noted that many patients with rhabdomyolysis develop both hypocalcemia, as well as 
elevated PRA levels during acute renal failure, consistent with the effects of Ca on renin that we 
have described.  Whether these changes in Ca are what initiate these changes in PRA remains 
unknown.  The level of hypercalcemia we achieve in our experiments is similar to that seen in 
patient populations, and as such, it likely provides an accurate model for many of the vascular 
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Renin is secreted from the juxtaglomerular (JG) cells of the afferent arteriole of the 
kidney, and is the rate-limiting enzyme of the renin-angiotensin system.  Renin is quantified in 
vivo as plasma renin activity (PRA).  Acutely elevating plasma calcium decreases PRA, but the 
mechanisms by which this occurs is unknown.  The overall goal of our study was to determine 
how elevated plasma calcium decreases PRA.  The calcium-sensing receptor (CaSR) is a 
ubiquitously expressed receptor that translates changes in plasma calcium into changes in 
intracellular signaling.  JG cells are basolaterally bordered by the renal cortical interstitium, and 
parathyroid hormone (PTH) positively regulates the concentration of calcium in the renal 
interstitium.  Thus, we hypothesized that hypercalcemia inhibits PRA via PTH-mediated 
increases in renal cortical interstitial Ca that act on the CaSR triggering Ca-mediated inhibition 
of renin secretion.  We demonstrated that the CaSR is expressed in JG cells in vivo.  
Additionally, we demonstrated that acutely stimulating the CaSR with pharmacological agonists 
decrease basal and stimulated PRA in anesthetized rats in parathyroid-intact and 
parathyroidectomized (PTX) rats.  We demonstrated that acute hypercalcemia decreased PRA, 
and that this inhibition of PRA is blocked by pharmacological CaSR antagonists and by PTX.  
72 
 
Acute supplementation of PTH did not affect the inhibition of PRA by high calcium.  Acute 
hypercalcemia increased renal cortical interstitial calcium, and this effect was blocked by PTX.  
This was likely due to decreased expression of the PTH-sensitive distal tubule calcium 
transporter TRPV5.  Lastly, we demonstrated that increasing renal sodium chloride delivery 
failed to increase renal cortical interstitial calcium, and that inhibiting thick ascending limb 
sodium chloride reabsorption with Furosemide increased PRA without effecting major changes 
in renal cortical interstitial calcium.  Our data support the notion that hypercalcemia inhibits 
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